CA2562580C - Drug-eluting tissue marker - Google Patents
Drug-eluting tissue marker Download PDFInfo
- Publication number
- CA2562580C CA2562580C CA2562580A CA2562580A CA2562580C CA 2562580 C CA2562580 C CA 2562580C CA 2562580 A CA2562580 A CA 2562580A CA 2562580 A CA2562580 A CA 2562580A CA 2562580 C CA2562580 C CA 2562580C
- Authority
- CA
- Canada
- Prior art keywords
- marker
- drug
- tissue
- hollow interior
- eluting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/34—Trocars; Puncturing needles
- A61B17/3468—Trocars; Puncturing needles for implanting or removing devices, e.g. prostheses, implants, seeds, wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00893—Material properties pharmaceutically effective
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3904—Markers, e.g. radio-opaque or breast lesions markers specially adapted for marking specified tissue
- A61B2090/3908—Soft tissue, e.g. breast tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Abstract
A drug-eluting tissue marker for marking a site in a tissue mass comprises a drug-eluting portion having a drug for timed release to the site and a material that can be imaged using an imaging technique.
Description
DRUG-ELUTING TISSUE MARKER
BACKGROUND OF THE INVENTION
Field of the Invention This invention relates generally to a marker for identifying a site in a tissue mass and particularly to a marker that can elute a drug. In another aspect, the invention relates to a method for introducing a drug-eluting marker into a tissue mass.
Description of the Related Art Tissue markers are implanted in tissue at a site of interest. The markers tend to be very small and biocompatible. They are most commonly implanted after a biopsy is performed to mark the location in case a further procedure at the site is needed. The markers are made of a material that can be imaged using an imaging technique such as magnetic resonance imaging, ultrasonography, or mammography.
Tissue at the site of implantation can be susceptible to related medical conditions such as infection or rejection of the marker, for example, because of the exposure of the tissue during the implantation procedure. There can also be damage to the tissue leading to and at the implantation site. The related medical conditions and tissue damage can require a separate treatment in addition to the implantation of the marker.
Some treatments require additional puncturing of the tissue to reach the implantation site for the application of drugs to address the condition or damage.
It is desirable to minimize the need to repuncture the tissue to treat a condition or damage at the implantation site.
SUMMARY OF THE INVENTION
According to the present invention, a tissue marker comprises a marker portion configured to mark a site within a tissue mass, a drug-eluting portion comprising a drug, and a body formed at least in part by the marker portion and the drug eluting portion and configured for implantation into the tissue mass.
The body can have a maximum dimension of 10 mm. The site can comprise a lesion and the body can be configured to mark a lesion having an effective size of at least 2mm.
At least one of the marker portion and the drug eluting portion can be imageable.
The marker portion can be imageable.
The marker can comprises a structure that resists migration of the marker from the site. The structure can be an anchor.
The marker portion can comprise a substrate and the drug-eluting portion can comprise a coating on the substrate.
The drug-eluting portion can be embedded in the marker portion. The marker portion can be bioabsorbable. The marker portion is configured to dissolve within the tissue mass at a predetermined rate and release the drug in a timed release fashion.
The marker portion can at least partially encapsulate the drug-eluting portion. The marker portion can comprise at least one opening that allows the drug to pass out of the marker portion. The marker portion can comprise a spring.
The body can comprise pores and the drug can be contained within the pores to form the drug-eluting portion.
The site can be one of a lesion and a biopsy site.
The drug can be one of an anti-inflammatory, antiplatelet, anticoagulant, antifebrin, antithrombin, cytostatic, antiproliferative, antibiotic, antimicrobial, antioxidant, antiallergic, antitumor, chemotherapeutic, antineoplastic, antimitotic, thrombolytic, fibrinolytic, vasodilator, antiviral, antihypertensive, antisecretory, immunosuppressive, growth factor, growth factor antagonist; antipolymerase, photodynamic therapy, antibody targeted therapy, prodrug, sex hormone, free radical scavengers, radiotherapeutic, radiopaque, radiolabelled, peptides, proteins, and enzyme substance, and any combination thereof.
According to another aspect of the invention, an imaging marker comprises a marker portion and a drug-eluting portion comprising a drug, with at least one of the marker portion and the drug-eluting portion being imageable.
The marker portion can comprise an imageable substrate and the drug-eluting portion can comprise a coating containing the drug applied to the substrate.
BACKGROUND OF THE INVENTION
Field of the Invention This invention relates generally to a marker for identifying a site in a tissue mass and particularly to a marker that can elute a drug. In another aspect, the invention relates to a method for introducing a drug-eluting marker into a tissue mass.
Description of the Related Art Tissue markers are implanted in tissue at a site of interest. The markers tend to be very small and biocompatible. They are most commonly implanted after a biopsy is performed to mark the location in case a further procedure at the site is needed. The markers are made of a material that can be imaged using an imaging technique such as magnetic resonance imaging, ultrasonography, or mammography.
Tissue at the site of implantation can be susceptible to related medical conditions such as infection or rejection of the marker, for example, because of the exposure of the tissue during the implantation procedure. There can also be damage to the tissue leading to and at the implantation site. The related medical conditions and tissue damage can require a separate treatment in addition to the implantation of the marker.
Some treatments require additional puncturing of the tissue to reach the implantation site for the application of drugs to address the condition or damage.
It is desirable to minimize the need to repuncture the tissue to treat a condition or damage at the implantation site.
SUMMARY OF THE INVENTION
According to the present invention, a tissue marker comprises a marker portion configured to mark a site within a tissue mass, a drug-eluting portion comprising a drug, and a body formed at least in part by the marker portion and the drug eluting portion and configured for implantation into the tissue mass.
The body can have a maximum dimension of 10 mm. The site can comprise a lesion and the body can be configured to mark a lesion having an effective size of at least 2mm.
At least one of the marker portion and the drug eluting portion can be imageable.
The marker portion can be imageable.
The marker can comprises a structure that resists migration of the marker from the site. The structure can be an anchor.
The marker portion can comprise a substrate and the drug-eluting portion can comprise a coating on the substrate.
The drug-eluting portion can be embedded in the marker portion. The marker portion can be bioabsorbable. The marker portion is configured to dissolve within the tissue mass at a predetermined rate and release the drug in a timed release fashion.
The marker portion can at least partially encapsulate the drug-eluting portion. The marker portion can comprise at least one opening that allows the drug to pass out of the marker portion. The marker portion can comprise a spring.
The body can comprise pores and the drug can be contained within the pores to form the drug-eluting portion.
The site can be one of a lesion and a biopsy site.
The drug can be one of an anti-inflammatory, antiplatelet, anticoagulant, antifebrin, antithrombin, cytostatic, antiproliferative, antibiotic, antimicrobial, antioxidant, antiallergic, antitumor, chemotherapeutic, antineoplastic, antimitotic, thrombolytic, fibrinolytic, vasodilator, antiviral, antihypertensive, antisecretory, immunosuppressive, growth factor, growth factor antagonist; antipolymerase, photodynamic therapy, antibody targeted therapy, prodrug, sex hormone, free radical scavengers, radiotherapeutic, radiopaque, radiolabelled, peptides, proteins, and enzyme substance, and any combination thereof.
According to another aspect of the invention, an imaging marker comprises a marker portion and a drug-eluting portion comprising a drug, with at least one of the marker portion and the drug-eluting portion being imageable.
The marker portion can comprise an imageable substrate and the drug-eluting portion can comprise a coating containing the drug applied to the substrate.
The marker portion can comprise a substrate of bioabsorbable material containing the drug.
The marker portion can comprise a substrate that at least partially encapsulates the drug.
According to yet another aspect of the invention, a method for marking a site within a tissue mass comprises placing a marker into the tissue mass and eluting a drug from the marker.
The placing step can comprise placing the marker at a lesion within the tissue mass. The placing step can comprise placing the marker at the site of a biopsy within the tissue mass.
The method can further comprise locating the marker after the placing step.
The locating step can comprise one of palpating the tissue mass and imaging the tissue mass. The method can further comprise conducting a medical procedure at the site after the locating step. The method can further comprising locating the site using an imaging system prior to the placing step. The placing step can comprise using an imaging system to embed the marker in a tissue mass.
According to another aspect, the present invention relates to an imaging marker comprising: a marker portion configured to mark a site within a soft tissue mass and a drug-eluting portion comprising a drug, with at least one of the marker portion and the drug-eluting portion being imageable; and a body formed at least in part by the marker portion and the drug-eluting portion, with the body configured for implantation into the soft tissue mass, wherein the marker portion comprises a structure that resists migration of the marker from the site; and wherein the imaging marker is suitable to be localized by palpation of the soft tissue mass.
According to another aspect, the present invention relates to the use of the imaging marker as defined herein for marking a site within a soft tissue mass.
The marker portion can comprise a substrate that at least partially encapsulates the drug.
According to yet another aspect of the invention, a method for marking a site within a tissue mass comprises placing a marker into the tissue mass and eluting a drug from the marker.
The placing step can comprise placing the marker at a lesion within the tissue mass. The placing step can comprise placing the marker at the site of a biopsy within the tissue mass.
The method can further comprise locating the marker after the placing step.
The locating step can comprise one of palpating the tissue mass and imaging the tissue mass. The method can further comprise conducting a medical procedure at the site after the locating step. The method can further comprising locating the site using an imaging system prior to the placing step. The placing step can comprise using an imaging system to embed the marker in a tissue mass.
According to another aspect, the present invention relates to an imaging marker comprising: a marker portion configured to mark a site within a soft tissue mass and a drug-eluting portion comprising a drug, with at least one of the marker portion and the drug-eluting portion being imageable; and a body formed at least in part by the marker portion and the drug-eluting portion, with the body configured for implantation into the soft tissue mass, wherein the marker portion comprises a structure that resists migration of the marker from the site; and wherein the imaging marker is suitable to be localized by palpation of the soft tissue mass.
According to another aspect, the present invention relates to the use of the imaging marker as defined herein for marking a site within a soft tissue mass.
According to another aspect, the present invention relates to a tissue marker, comprising: a marker portion configured to mark a site within a soft tissue mass, the marker portion having a length extending along a centerline of the marker portion between a first end and a second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior; and a drug-eluting portion comprising a drug, wherein the drug-eluting portion is disposed within the hollow interior; wherein the length of the marker portion is greater than an average diameter of the hollow interior and wherein the substantially continuous wall includes at least one opening adapted to allow the drug to pass out of the hollow interior.
According to another aspect, the present invention relates to an imaging marker comprising a marker portion and a drug-eluting portion comprising a drug, with the marker portion, the drug-eluting portion, or both, being imageable, the marker portion having a length extending along a centerline of the marker portion between a first end and a second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior and at least partially encapsulating the drug eluting portion within the hollow interior, and wherein the length of the marker portion is greater than an average diameter of the hollow interior and the substantially continuous wall includes at least one opening adapted to allow the drug to pass out of the hollow interior.
According to another aspect, the present invention relates to use of a marker for marking a site within a soft tissue mass, wherein the marker has a length extending along a centerline of the marker between a first end and a second end and has a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior and at least partially encapsulating a drug within the hollow interior, and wherein the length of the marker is greater than an average diameter of the hollow interior and the substantially continuous wall includes at least one opening adapted to allow the drug to pass out of the hollow interior; and eluting the drug from the marker and wherein the marker is suitable for placement into a soft tissue mass.
- 3a -According to another aspect, the present invention relates to a tissue marker, comprising: a marker portion configured to mark a site within a soft tissue mass, the marker portion being formed as a body having open ends, and having a substantially continuous wall bounding a hollow interior; and a drug-eluting portion comprising a drug, wherein the drug-eluting portion is disposed within the hollow interior of the body, and wherein the open ends facilitate a passing of the drug out of the hollow interior of the body to a region outside the body; and wherein the body is in the form of a tube having a plurality of openings that extend through the wall, and wherein the plurality of openings facilitate the passing of the drug out of the hollow interior of the tube to the region outside the tube.
According to another aspect, the present invention relates to a tissue marking apparatus, comprising: a marker introducer that includes a cannula and a stylet, the cannula having a lumen and a marker exit port, and the stylet being slidably received in the lumen, the stylet having a distal end; and a tissue marker configured to be received in the lumen distal to the distal end of the stylet, the tissue marker including: a marker portion configured to mark a site within a soft tissue mass, the marker portion having a length extending along a centerline of the marker portion between a first end and a second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior; and a drug-eluting portion comprising a drug, wherein the substantially continuous wall that bounds the hollow interior includes at least one opening configured to allow the drug to pass out of the hollow interior.
According to another aspect, the present invention relates to a tissue marking apparatus, comprising: a marker introducer that includes a cannula and a stylet, the cannula having a lumen and a marker exit port, and the stylet being slidably received in the lumen, the stylet having a distal end; and an imaging marker configured to be received in the lumen distal to the distal end of the stylet, the imaging marker including a marker portion and a drug-eluting portion, with at least one of the marker portion and the drug-eluting portion being imageable, the marker portion having a length extending along a centerline of the marker portion between a first end and a - 3b -second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior and at least partially encapsulating the drug eluting portion within the hollow interior, and wherein the length of the marker portion is greater than an average diameter of the hollow interior and the substantially continuous wall includes at least one opening adapted to allow the drug to pass out of the hollow interior.
According to another aspect, the present invention relates a tissue marking apparatus, comprising: a marker introducer that includes a cannula and a stylet, the cannula having a lumen and a marker exit port, and the stylet being slidably received in the lumen, the stylet having a distal end; and a tissue marker configured to be received in the lumen distal to the distal end of the stylet, the tissue marker including: a marker portion configured to mark a site within a soft tissue mass, the marker portion being formed as a body having open ends, and having a substantially continuous wall bounding a hollow interior; and a drug-eluting portion comprising a drug, wherein the drug-eluting portion is disposed within the hollow interior of the body, and wherein the open ends facilitate a passing of the drug out of the hollow interior of the body to a region outside the body; and wherein the body is in the form of a tube having a plurality of openings that extend through the wall, and wherein the plurality of openings facilitate the passing of the drug out of the hollow interior of the tube to the region outside the tube.
BRIEF DESCRIPTION OF THE DRAWINGS
In the drawings:
FIG. 1 is a plan view of an introducer used to place a drug-eluting tissue marker at a location in a tissue mass in accordance with the invention;
FIG. 2 is an enlarged sectional view of area II of FIG. 1 illustrating the position of a drug-eluting marker within the introducer prior to ejection;
FIG. 3 is an assembly view of are III of FIG. 4 illustrating the arrangement of a handle, a plunger, a cannula, and a stylet of the introducer;
- 3c -FIG. 4 is a sectional view taken along line 4-4 of FIG. 1 and illustrating the introducer in a ready condition;
FIG. 5 is a sectional view taken along line 4-4 of FIG. 1 and illustrating the introducer in a discharged condition;
FIG. 6 is a partially broken away perspective view, greatly enlarged, of a first embodiment of the drug-eluting marker according to the invention;
- 3d -FIG. 7 is an enlarged view of a second embodiment of the drug-eluting marker according to the invention;
FIG. 8 is an enlarged view of a third embodiment of the drug-eluting marker according to the invention; and FIG. 9 is an enlarged view of an alternate design for the third embodiment of the drug-eluting marker according to the invention.
DESCRIPTION OF THE PREFERRED EMBODIMENT
FIGS. 1-4 illustrate a marking apparatus 10 according to the invention, which is capable of the percutaneous placement of a drug-eluting tissue marker 60 at a site within in a tissue mass according to the invention. Exemplary tissue masses include breast tissue, skin tissue, muscle tissue, the tissue of glands, such as the prostate, and the tissue of organs such as the lungs, kidney, and liver. For purposes of this application, these types of tissue masses are referred to as soft tissue, which expressly excludes vascular structures.
In the following example, the marking apparatus 10 can be used to place a marker 60 at the location of a tissue biopsy or a lesion. The marking apparatus 10 comprises an introducer 12 and a drug-eluting marker 60 (FIG. 2) contained within the introducer 12.
The drug-eluting marker 12 marks a site in a tissue mass. It preferably does not perform a prosthetic function, such as structurally or functionally replacing a part of the tissue mass.
The introducer 12 includes a handle 16 having a hollow interior 18. The handle comprises a grip portion 20 from which extends a tapered nose portion 22. The grip portion 20 defines a rear opening 24 that provides access to the hollow interior 18. A pair of detents 26 are formed in the grip portion 20 near the rear opening 24.
Channels 28 are formed on the interior surface of the grip portion 20 and extend from the rear opening 24 to the detents 26.
The nose portion 22 comprises a guide passage 30 extending from the tip of the nose portion 22 to the hollow interior 18 of the handle 16. The guide passage 30 decreases in diameter inwardly from the tip of the nose portion to form a cannula seat 32.
Alternatively, the diameter of the guide passage 30 may be substantially equal to or slightly smaller than the outer diameter of a cannula 34, which in any case is press-fit within the cannula seat 32. As is customary, the cannula is formed with a hollow interior 36 and a sharpened tip 38.
A stylet 40 comprising a shaft 42 and a base 44 is received within the hollow interior 18 of the handle 16 in a manner such that the shaft 42 extends through the guide passage 30 and into the cannula interior 36 and the stylet base lies within the hollow interior 18.
A plunger 50 comprises a cylindrical body 52 from which extends a pair of catches 54 at diametrically opposed positions. The cylindrical body 52 is preferably sized so that it is slidably received within the rear opening 24 of the handle where it is so oriented with respect to the handle that the catches 54 are aligned with the guide channels 28.
It should be noted that the marking apparatus 10 is just one example of an apparatus for implanting the marker 60. Many other delivery systems and devices can also be used to implant the drug-eluting marker 60. For example the marker 60 can be implanted in the tissue through a flexible sheath introduced through a vacuum assisted biopsy (VAB) device.
In operation, the introducer 12 begins in the ready condition shown in FIG.
4. In this condition, the stylet shaft is received within the cannula but does not extend to the cannula tip 38 thereby forming a marker recess 46 within the cannula 34, the drug-eluting marker 60 is disposed within the marker recess 46, and the plunger 50 is in a position relative to the handle 20 in which the catches 54 are outside the handle 16; that is, the catches 54 are not received within the detents 26. However, the plunger 50 is so oriented with respect to the handle that the catches 54 are aligned with the guide channels 28.
With the introducer in the ready condition, the cannula is positioned so that its tip is at or near the location of a tissue mass where a biopsy has been taken.
Preferably, the cannula tip is positioned by using an imaging system. The cannula tip 38 can be designed for enhanced visibility using common imaging systems, such as CAT scan, ultrasonography and mammography. Suitable cannula tips are disclosed in U.S. Patent No. 5,490,521, issued February 13, 1996 to R. E.
Davis and G. L. McLellan. Ultrasound enhancement technology is also disclosed in U.S.
Patent No. 4,401,124, issued August 30, 1983 to J. F. Guess, D. R. Dietz, and C.
F. Hollinger; and U.S. Patent No. 4,582,061, issued April 15, 1986 to F. J.
Fry.
- 5a -Once the cannula is positioned at the desired location, the plunger 50 is moved from its first or ready condition as illustrated in FIGS. 1 to 4 to a second or discharged condition as illustrated in FIG. 5 in which the catches 54 are received within the detents 26 to lock the plunger 50 in the discharged condition and the stylet shaft extends beyond the cannula tip 38. The catches 50 and detents combine to function as a latch for locking the plunger in the discharged condition. As the plunger 50 is moved from the ready condition to the discharged condition, the plunger 50 drives the stylet base 44 forward to advance the stylet shaft 42 within the cannula interior 36. As the stylet shaft 42 is advanced, the drug-eluting marker 60 is ejected from the marker recess 46 through the cannula tip 38 and into the tissue at the biopsy location.
The cannula 34 is illustrated with an opening formed in the cannula tip 38 communicating with the hollow interior 36; however the cannula 34 can optionally have an opening in a side wall of the cannula 34 that communicates with the hollow interior 36 and a closed tip 38, such that the drug-eluting marker 60 is ejected from the marker recess 46 through the side wall opening.
The drug-eluting tissue marker 60 is preferably readily imaged using contemporary imaging techniques. For example, the marker 60 can be made of material suitable to be imaged using X-ray, mammography, ultrasound, fluoroscopy, computed tomography, magnetic resonance imaging (MRI), computerized axial tomography (CAT) scan, Doppler, radiation detector, and any possible combination thereof. Optionally, the marker can be detectable by palpation of the overlying tissue or visualization of the marker using a colored material that is different that the surrounding tissue and blood.
Regardless of the means, the marker 60 should be readily locatable within the tissue mass.
Additionally, the marker 60 should not migrate within the tissue from the position in which it is initially placed. The marker 60 should be precisely and accurately locatable at the site, in case an additional medical procedure is needed. Returning to the biopsy example, if a tissue sample taken from a biopsy site is determined to be malignant or the pathology is inconclusive, an additional medical procedure at the site is necessary, in which case it is important to be able to locate the biopsy site.
The size and shape of the marker 60 can vary according to the application in which it is used. For example, lesions can have an effective size ranging from 2mm to several centimeters, and thus the size and shape of the marker 60 can be configured according to the lesion size. As used herein, the term lesion has its normal meaning and expressly includes one or more micro-calcifications. The size of marker 60 has a practical upper limit that is related to the following factors. At some point the lesion will be large enough that it is palpable even after it is biopsied. For immediate relocating, such a lesion will not require the use of a marker as a surgeon or other practitioner will be able to find the lesion by palpitation. However, it still may be desirable to place a marker in anticipation of the lesion being reduced by future treatment, such as radiation. The marker should be large enough for easy location using the imaging system of choice, but should not be so big that it will obscure or interfere with imaging the lesion site. For these larger but not easily palpable lesions, a larger marker can be used without interfering with the imaging of the lesion site. For current imaging systems the useful upper size limit is about 10 mm for the maximum dimension, whereas the lower size limit is about 1 mm for the minimum dimension. By way of example, and without limitation, the marker 60 can have a length of about 3mm and a width of about 1.5 mm.
FIGS. 6-9 illustrate four possible embodiments of the drug-eluting tissue marker 60; however, it is understood that the configuration of the marker 60 is not limiting to the invention and many other configurations of the marker 60 are possible without departing from the scope of the invention. For example, the marker 60 can have a hollow interior for enhanced imaging characteristics. Examples of other shapes are shown in U.S.
Patents 6,575,991; 6,371,904; 6,261,243; 6,228,055; and 6,056,700.
A first embodiment of the marker 60 is shown in FIG. 6 having a bight portion from which extend legs 67, which terminate in tips 68. The tips 68 extend in opposite directions to function as anchors for the marker 60 and help prevent the marker 60 from migrating from the site. The marker 60 further comprises a substrate 62 (partially shown) of underlying material that is coated with a drug 64. As used herein, the term "drug" can include any therapeutic agent, pharmacologic agent, or other substance used for the diagnosis, treatment, or prevention of a disease or as a component of a medication. A
coating of the drug 64 can be deposited on the substrate surface using any suitable deposition technique. Alternately, the drug 64 can be embedded in a suitable material, such as a polymer, for timed release of the drug 64. At least a portion of the marker 60 is locatable from the exterior of the patient, through palpitation or through use of an imaging system.
The substrate 62 can be any number of materials that are suitably biocompatible and appropriate for the type of drug deposited on the substrate surface. The underlying material can be imageable to perform the marking function. Examples of materials for the substrate 62 include: stainless steel, tantalum, titanium, nitinol, gold, platinum, inconel, iridium, rhodium, silver, tungsten, or another biocompatible metal, or alloys of any of these; carbon or carbon fiber; cellulose acetate, cellulose nitrate, silicone, polyethylene teraphthalate, polyurethane, polyamide, polyester, polyorthoester, polyanhydride, polyether sulfone, polycarbonate, polypropylene, high molecular weight polyethylene, polytetrafluoroethylene, or another biocompatible polymeric material, or mixtures or copolymers thereof; polylactic acid, polyglycolic acid or copolymers thereof, a polyanhydride, polycaprolactone, polyhydroxy-butyrate valerate or another biodegradable polymer, or mixtures or copolymers of these; a protein, an extracellular matrix component, collagen, fibrin or another biologic agent; or a mixture thereof.
Some of these materials cannot be imaged using one of the aforementioned imaging techniques. In this case, an imageable material can be added to the drug coating 64 to enhance the radiopaque, mammographic, echogenic, etc. characteristics of the marker, allowing the marker to be observed with a corresponding imaging technique. For example, a contrast material such as iodine can be added to the coating to make the marker imageable during a CAT scan. Alternately, a separate coating can be deposited on the marker 60 in addition to the drug coating 64 to make the marker imageable.
Examples of the drug 64 include: anti-inflammatory, antiplatelet, anticoagulant, antifebrin, antithrombin, cytostatic, antiproliferative, antibiotic, antimicrobial, antioxidant, and antiallergic substances; antitumor and/or chemotherapeutic agents, including antineoplastic and antimitotic agents; thrombolytics; fibrinolytics, vasodilators; antiviral, antihypertensive, antisecretory, and immunosuppressive agents; growth factors and growth factor antagonists; antipolymerases; photodynamic therapy and antibody targeted therapy agents; prodrugs; sex hormones; free radical scavengers; radiotherapeutic, radiopaque, and radiolabelled agents; and peptides, proteins, and enzymes. Further, any combination of drugs, therapeutic agents, or other substances can be used to coat the marker of the present invention.
Examples of such anti-inflammatory substances include estradiol, aspirin, ibuprofen, and naproxen.
Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin, prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), Dipyridamole, glycoprotein Hb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, thrombin inhibitors such as Angiomax.TM. (Biogen, Inc., Cambridge, Mass.), glycoprotein IIbIIIa inhibitors, ticlopidine, clopidigrel, warfarin (e.g. Coumadin0 from Bristol-Myers Squibb Co., Stamford, Conn.), aspirin, and hirulog.
Examples of such cytostatic or antiproliferative agents include, actinomycin D
as well as derivatives and analogs thereof (manufactured by Sigma-Aldrich, Milwaukee, Wis.; or COSMEGEN0 available from Merck & Co., Inc., Whitehouse Station, N.J.), angiopeptin, mitomycin, angiotensin converting enzyme inhibitors such as captopril (e.g., Capoten0 and Capozide from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g., Prinivil and Prinzide0 from Merck & Co., Inc., Whitehouse Station, N.J.), calcium channel blockers (such as nifedipine), colchicines, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMB-CoA reductase, a cholesterol lowering drug, brand name Mevacor from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide.
Examples of such antiallergic substances include permirolast potassium, and tranilast.
Examples of such antitumor and/or chemotherapeutic agents include 2-chlorodeoxyadenosine (also known as cladribine), 6-thioguanine (also known as 2-amino-6-mercaptopurine), 13-cis-retinoic acid (also known as isoretinoin), aldesleukin (also known as interleukin-2), alemtuzumab, alitretinoin, all-trans retinoic acid (also known as tretinoin), alpha interferon, altretamine (also known as hexamethylmelamine), amifostine, aminoglutethimide, anagrelide, anastrozole, arsenic trioxide, asparaginase, azacitidine, azathioprine, BCG (Bacillus Calmette-Guerin), bevacizumab, bexarotene, bicalutamide, bleomycin, bortezomib, busulfan, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cyclophosphamide, cytarabine (also known as arabinosylcytosine), cytarabine liposomal, dacarbazine, dactinomycin, daunorubicin liposomal, darbepoetin alfa, daunorubicin, decitabine, denileukin diftitox, dexamethasone (also known as dexamethasone sodium phosphate and dexamethasone acetate), dexrazoxane, docetaxel (e.g., Taxotere from Aventis S.A., Frankfurt, Germany), doxorubicin, doxorubicin hydrochloride (e.g., Adriamycin from Pharmacia & Upjohn, Peapack, N.J.), doxorubicin liposomal, epirubicin, epoetin alfa, estramustine, erlotinib, etoposide, exemestane, filgrastim, fluorouracil (also known as 5-fluorouracil), floxuridine, fludarabine, fluoxymesterone, flutamide, fulvestrant, gefitinib, gemcitabine, gemtuzumab, goserelin, ozogamicin, hydrocortisone (also known as cortisone), hydroxyurea, ibritumomab (also known as ibritumomab tiuxetan), idarubicin, ifosfamide, imatinib mesylate, irinotecan, lenalidomide, letrozole, leucovorin, leuprolide, lomustine, mechlorethamine (also known as nitrogen mustard, mustine, and mechlorethamine hydrochloride), megestrol (also known as megestrol acetate), melphalan, mercaptopurine (also known as 6-mercaptopurine), methotrexate (also known as amethopterin and methotrexate sodium), methylprednisolone, mesna, mitomycin (e.g., Mutamycin0 from Bristol-Myers Squibb Co., Stamford, Conn.), mitoxantrone, nelarabine, nilutamide, octreotide (also known as octreotide acetate), oprevelkin, oxaliplatin, paclitaxel (e.g., TAXOL by Bristol-Myers Squibb Co., Stamford, Conn.), paclitaxel protein-bound, pamidronate, peg interferon, pegaspargase, pegfilgrastim, pemetrexed, pentostatin, prednisolone, prednisone, procarbazine, raloxifene, rituximab, sargramostim, sorafenib, streptozocin, sunitinib, tamoxifen, temozolomide, teniposide, thalidomide, thiotepa (also known as thiophosphoamide), topotecan, toremifene, tositumomab (also known as iodine I ¨ 131), trastuzumab, vinblastine, vincristine, vinorelbine, and zoledronic acid.
Examples of such thrombolytics and/or fibrinolytics include tissue plasminogen activator (tPA), recombinant tPA, urokinase, streptokinase, tenecteplase, alteplase (e.g.
Activase from Genentech, Inc., San Francisco, CA), lysatec, antistreplase (e.g.
According to another aspect, the present invention relates to an imaging marker comprising a marker portion and a drug-eluting portion comprising a drug, with the marker portion, the drug-eluting portion, or both, being imageable, the marker portion having a length extending along a centerline of the marker portion between a first end and a second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior and at least partially encapsulating the drug eluting portion within the hollow interior, and wherein the length of the marker portion is greater than an average diameter of the hollow interior and the substantially continuous wall includes at least one opening adapted to allow the drug to pass out of the hollow interior.
According to another aspect, the present invention relates to use of a marker for marking a site within a soft tissue mass, wherein the marker has a length extending along a centerline of the marker between a first end and a second end and has a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior and at least partially encapsulating a drug within the hollow interior, and wherein the length of the marker is greater than an average diameter of the hollow interior and the substantially continuous wall includes at least one opening adapted to allow the drug to pass out of the hollow interior; and eluting the drug from the marker and wherein the marker is suitable for placement into a soft tissue mass.
- 3a -According to another aspect, the present invention relates to a tissue marker, comprising: a marker portion configured to mark a site within a soft tissue mass, the marker portion being formed as a body having open ends, and having a substantially continuous wall bounding a hollow interior; and a drug-eluting portion comprising a drug, wherein the drug-eluting portion is disposed within the hollow interior of the body, and wherein the open ends facilitate a passing of the drug out of the hollow interior of the body to a region outside the body; and wherein the body is in the form of a tube having a plurality of openings that extend through the wall, and wherein the plurality of openings facilitate the passing of the drug out of the hollow interior of the tube to the region outside the tube.
According to another aspect, the present invention relates to a tissue marking apparatus, comprising: a marker introducer that includes a cannula and a stylet, the cannula having a lumen and a marker exit port, and the stylet being slidably received in the lumen, the stylet having a distal end; and a tissue marker configured to be received in the lumen distal to the distal end of the stylet, the tissue marker including: a marker portion configured to mark a site within a soft tissue mass, the marker portion having a length extending along a centerline of the marker portion between a first end and a second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior; and a drug-eluting portion comprising a drug, wherein the substantially continuous wall that bounds the hollow interior includes at least one opening configured to allow the drug to pass out of the hollow interior.
According to another aspect, the present invention relates to a tissue marking apparatus, comprising: a marker introducer that includes a cannula and a stylet, the cannula having a lumen and a marker exit port, and the stylet being slidably received in the lumen, the stylet having a distal end; and an imaging marker configured to be received in the lumen distal to the distal end of the stylet, the imaging marker including a marker portion and a drug-eluting portion, with at least one of the marker portion and the drug-eluting portion being imageable, the marker portion having a length extending along a centerline of the marker portion between a first end and a - 3b -second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior and at least partially encapsulating the drug eluting portion within the hollow interior, and wherein the length of the marker portion is greater than an average diameter of the hollow interior and the substantially continuous wall includes at least one opening adapted to allow the drug to pass out of the hollow interior.
According to another aspect, the present invention relates a tissue marking apparatus, comprising: a marker introducer that includes a cannula and a stylet, the cannula having a lumen and a marker exit port, and the stylet being slidably received in the lumen, the stylet having a distal end; and a tissue marker configured to be received in the lumen distal to the distal end of the stylet, the tissue marker including: a marker portion configured to mark a site within a soft tissue mass, the marker portion being formed as a body having open ends, and having a substantially continuous wall bounding a hollow interior; and a drug-eluting portion comprising a drug, wherein the drug-eluting portion is disposed within the hollow interior of the body, and wherein the open ends facilitate a passing of the drug out of the hollow interior of the body to a region outside the body; and wherein the body is in the form of a tube having a plurality of openings that extend through the wall, and wherein the plurality of openings facilitate the passing of the drug out of the hollow interior of the tube to the region outside the tube.
BRIEF DESCRIPTION OF THE DRAWINGS
In the drawings:
FIG. 1 is a plan view of an introducer used to place a drug-eluting tissue marker at a location in a tissue mass in accordance with the invention;
FIG. 2 is an enlarged sectional view of area II of FIG. 1 illustrating the position of a drug-eluting marker within the introducer prior to ejection;
FIG. 3 is an assembly view of are III of FIG. 4 illustrating the arrangement of a handle, a plunger, a cannula, and a stylet of the introducer;
- 3c -FIG. 4 is a sectional view taken along line 4-4 of FIG. 1 and illustrating the introducer in a ready condition;
FIG. 5 is a sectional view taken along line 4-4 of FIG. 1 and illustrating the introducer in a discharged condition;
FIG. 6 is a partially broken away perspective view, greatly enlarged, of a first embodiment of the drug-eluting marker according to the invention;
- 3d -FIG. 7 is an enlarged view of a second embodiment of the drug-eluting marker according to the invention;
FIG. 8 is an enlarged view of a third embodiment of the drug-eluting marker according to the invention; and FIG. 9 is an enlarged view of an alternate design for the third embodiment of the drug-eluting marker according to the invention.
DESCRIPTION OF THE PREFERRED EMBODIMENT
FIGS. 1-4 illustrate a marking apparatus 10 according to the invention, which is capable of the percutaneous placement of a drug-eluting tissue marker 60 at a site within in a tissue mass according to the invention. Exemplary tissue masses include breast tissue, skin tissue, muscle tissue, the tissue of glands, such as the prostate, and the tissue of organs such as the lungs, kidney, and liver. For purposes of this application, these types of tissue masses are referred to as soft tissue, which expressly excludes vascular structures.
In the following example, the marking apparatus 10 can be used to place a marker 60 at the location of a tissue biopsy or a lesion. The marking apparatus 10 comprises an introducer 12 and a drug-eluting marker 60 (FIG. 2) contained within the introducer 12.
The drug-eluting marker 12 marks a site in a tissue mass. It preferably does not perform a prosthetic function, such as structurally or functionally replacing a part of the tissue mass.
The introducer 12 includes a handle 16 having a hollow interior 18. The handle comprises a grip portion 20 from which extends a tapered nose portion 22. The grip portion 20 defines a rear opening 24 that provides access to the hollow interior 18. A pair of detents 26 are formed in the grip portion 20 near the rear opening 24.
Channels 28 are formed on the interior surface of the grip portion 20 and extend from the rear opening 24 to the detents 26.
The nose portion 22 comprises a guide passage 30 extending from the tip of the nose portion 22 to the hollow interior 18 of the handle 16. The guide passage 30 decreases in diameter inwardly from the tip of the nose portion to form a cannula seat 32.
Alternatively, the diameter of the guide passage 30 may be substantially equal to or slightly smaller than the outer diameter of a cannula 34, which in any case is press-fit within the cannula seat 32. As is customary, the cannula is formed with a hollow interior 36 and a sharpened tip 38.
A stylet 40 comprising a shaft 42 and a base 44 is received within the hollow interior 18 of the handle 16 in a manner such that the shaft 42 extends through the guide passage 30 and into the cannula interior 36 and the stylet base lies within the hollow interior 18.
A plunger 50 comprises a cylindrical body 52 from which extends a pair of catches 54 at diametrically opposed positions. The cylindrical body 52 is preferably sized so that it is slidably received within the rear opening 24 of the handle where it is so oriented with respect to the handle that the catches 54 are aligned with the guide channels 28.
It should be noted that the marking apparatus 10 is just one example of an apparatus for implanting the marker 60. Many other delivery systems and devices can also be used to implant the drug-eluting marker 60. For example the marker 60 can be implanted in the tissue through a flexible sheath introduced through a vacuum assisted biopsy (VAB) device.
In operation, the introducer 12 begins in the ready condition shown in FIG.
4. In this condition, the stylet shaft is received within the cannula but does not extend to the cannula tip 38 thereby forming a marker recess 46 within the cannula 34, the drug-eluting marker 60 is disposed within the marker recess 46, and the plunger 50 is in a position relative to the handle 20 in which the catches 54 are outside the handle 16; that is, the catches 54 are not received within the detents 26. However, the plunger 50 is so oriented with respect to the handle that the catches 54 are aligned with the guide channels 28.
With the introducer in the ready condition, the cannula is positioned so that its tip is at or near the location of a tissue mass where a biopsy has been taken.
Preferably, the cannula tip is positioned by using an imaging system. The cannula tip 38 can be designed for enhanced visibility using common imaging systems, such as CAT scan, ultrasonography and mammography. Suitable cannula tips are disclosed in U.S. Patent No. 5,490,521, issued February 13, 1996 to R. E.
Davis and G. L. McLellan. Ultrasound enhancement technology is also disclosed in U.S.
Patent No. 4,401,124, issued August 30, 1983 to J. F. Guess, D. R. Dietz, and C.
F. Hollinger; and U.S. Patent No. 4,582,061, issued April 15, 1986 to F. J.
Fry.
- 5a -Once the cannula is positioned at the desired location, the plunger 50 is moved from its first or ready condition as illustrated in FIGS. 1 to 4 to a second or discharged condition as illustrated in FIG. 5 in which the catches 54 are received within the detents 26 to lock the plunger 50 in the discharged condition and the stylet shaft extends beyond the cannula tip 38. The catches 50 and detents combine to function as a latch for locking the plunger in the discharged condition. As the plunger 50 is moved from the ready condition to the discharged condition, the plunger 50 drives the stylet base 44 forward to advance the stylet shaft 42 within the cannula interior 36. As the stylet shaft 42 is advanced, the drug-eluting marker 60 is ejected from the marker recess 46 through the cannula tip 38 and into the tissue at the biopsy location.
The cannula 34 is illustrated with an opening formed in the cannula tip 38 communicating with the hollow interior 36; however the cannula 34 can optionally have an opening in a side wall of the cannula 34 that communicates with the hollow interior 36 and a closed tip 38, such that the drug-eluting marker 60 is ejected from the marker recess 46 through the side wall opening.
The drug-eluting tissue marker 60 is preferably readily imaged using contemporary imaging techniques. For example, the marker 60 can be made of material suitable to be imaged using X-ray, mammography, ultrasound, fluoroscopy, computed tomography, magnetic resonance imaging (MRI), computerized axial tomography (CAT) scan, Doppler, radiation detector, and any possible combination thereof. Optionally, the marker can be detectable by palpation of the overlying tissue or visualization of the marker using a colored material that is different that the surrounding tissue and blood.
Regardless of the means, the marker 60 should be readily locatable within the tissue mass.
Additionally, the marker 60 should not migrate within the tissue from the position in which it is initially placed. The marker 60 should be precisely and accurately locatable at the site, in case an additional medical procedure is needed. Returning to the biopsy example, if a tissue sample taken from a biopsy site is determined to be malignant or the pathology is inconclusive, an additional medical procedure at the site is necessary, in which case it is important to be able to locate the biopsy site.
The size and shape of the marker 60 can vary according to the application in which it is used. For example, lesions can have an effective size ranging from 2mm to several centimeters, and thus the size and shape of the marker 60 can be configured according to the lesion size. As used herein, the term lesion has its normal meaning and expressly includes one or more micro-calcifications. The size of marker 60 has a practical upper limit that is related to the following factors. At some point the lesion will be large enough that it is palpable even after it is biopsied. For immediate relocating, such a lesion will not require the use of a marker as a surgeon or other practitioner will be able to find the lesion by palpitation. However, it still may be desirable to place a marker in anticipation of the lesion being reduced by future treatment, such as radiation. The marker should be large enough for easy location using the imaging system of choice, but should not be so big that it will obscure or interfere with imaging the lesion site. For these larger but not easily palpable lesions, a larger marker can be used without interfering with the imaging of the lesion site. For current imaging systems the useful upper size limit is about 10 mm for the maximum dimension, whereas the lower size limit is about 1 mm for the minimum dimension. By way of example, and without limitation, the marker 60 can have a length of about 3mm and a width of about 1.5 mm.
FIGS. 6-9 illustrate four possible embodiments of the drug-eluting tissue marker 60; however, it is understood that the configuration of the marker 60 is not limiting to the invention and many other configurations of the marker 60 are possible without departing from the scope of the invention. For example, the marker 60 can have a hollow interior for enhanced imaging characteristics. Examples of other shapes are shown in U.S.
Patents 6,575,991; 6,371,904; 6,261,243; 6,228,055; and 6,056,700.
A first embodiment of the marker 60 is shown in FIG. 6 having a bight portion from which extend legs 67, which terminate in tips 68. The tips 68 extend in opposite directions to function as anchors for the marker 60 and help prevent the marker 60 from migrating from the site. The marker 60 further comprises a substrate 62 (partially shown) of underlying material that is coated with a drug 64. As used herein, the term "drug" can include any therapeutic agent, pharmacologic agent, or other substance used for the diagnosis, treatment, or prevention of a disease or as a component of a medication. A
coating of the drug 64 can be deposited on the substrate surface using any suitable deposition technique. Alternately, the drug 64 can be embedded in a suitable material, such as a polymer, for timed release of the drug 64. At least a portion of the marker 60 is locatable from the exterior of the patient, through palpitation or through use of an imaging system.
The substrate 62 can be any number of materials that are suitably biocompatible and appropriate for the type of drug deposited on the substrate surface. The underlying material can be imageable to perform the marking function. Examples of materials for the substrate 62 include: stainless steel, tantalum, titanium, nitinol, gold, platinum, inconel, iridium, rhodium, silver, tungsten, or another biocompatible metal, or alloys of any of these; carbon or carbon fiber; cellulose acetate, cellulose nitrate, silicone, polyethylene teraphthalate, polyurethane, polyamide, polyester, polyorthoester, polyanhydride, polyether sulfone, polycarbonate, polypropylene, high molecular weight polyethylene, polytetrafluoroethylene, or another biocompatible polymeric material, or mixtures or copolymers thereof; polylactic acid, polyglycolic acid or copolymers thereof, a polyanhydride, polycaprolactone, polyhydroxy-butyrate valerate or another biodegradable polymer, or mixtures or copolymers of these; a protein, an extracellular matrix component, collagen, fibrin or another biologic agent; or a mixture thereof.
Some of these materials cannot be imaged using one of the aforementioned imaging techniques. In this case, an imageable material can be added to the drug coating 64 to enhance the radiopaque, mammographic, echogenic, etc. characteristics of the marker, allowing the marker to be observed with a corresponding imaging technique. For example, a contrast material such as iodine can be added to the coating to make the marker imageable during a CAT scan. Alternately, a separate coating can be deposited on the marker 60 in addition to the drug coating 64 to make the marker imageable.
Examples of the drug 64 include: anti-inflammatory, antiplatelet, anticoagulant, antifebrin, antithrombin, cytostatic, antiproliferative, antibiotic, antimicrobial, antioxidant, and antiallergic substances; antitumor and/or chemotherapeutic agents, including antineoplastic and antimitotic agents; thrombolytics; fibrinolytics, vasodilators; antiviral, antihypertensive, antisecretory, and immunosuppressive agents; growth factors and growth factor antagonists; antipolymerases; photodynamic therapy and antibody targeted therapy agents; prodrugs; sex hormones; free radical scavengers; radiotherapeutic, radiopaque, and radiolabelled agents; and peptides, proteins, and enzymes. Further, any combination of drugs, therapeutic agents, or other substances can be used to coat the marker of the present invention.
Examples of such anti-inflammatory substances include estradiol, aspirin, ibuprofen, and naproxen.
Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin, prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), Dipyridamole, glycoprotein Hb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, thrombin inhibitors such as Angiomax.TM. (Biogen, Inc., Cambridge, Mass.), glycoprotein IIbIIIa inhibitors, ticlopidine, clopidigrel, warfarin (e.g. Coumadin0 from Bristol-Myers Squibb Co., Stamford, Conn.), aspirin, and hirulog.
Examples of such cytostatic or antiproliferative agents include, actinomycin D
as well as derivatives and analogs thereof (manufactured by Sigma-Aldrich, Milwaukee, Wis.; or COSMEGEN0 available from Merck & Co., Inc., Whitehouse Station, N.J.), angiopeptin, mitomycin, angiotensin converting enzyme inhibitors such as captopril (e.g., Capoten0 and Capozide from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g., Prinivil and Prinzide0 from Merck & Co., Inc., Whitehouse Station, N.J.), calcium channel blockers (such as nifedipine), colchicines, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMB-CoA reductase, a cholesterol lowering drug, brand name Mevacor from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide.
Examples of such antiallergic substances include permirolast potassium, and tranilast.
Examples of such antitumor and/or chemotherapeutic agents include 2-chlorodeoxyadenosine (also known as cladribine), 6-thioguanine (also known as 2-amino-6-mercaptopurine), 13-cis-retinoic acid (also known as isoretinoin), aldesleukin (also known as interleukin-2), alemtuzumab, alitretinoin, all-trans retinoic acid (also known as tretinoin), alpha interferon, altretamine (also known as hexamethylmelamine), amifostine, aminoglutethimide, anagrelide, anastrozole, arsenic trioxide, asparaginase, azacitidine, azathioprine, BCG (Bacillus Calmette-Guerin), bevacizumab, bexarotene, bicalutamide, bleomycin, bortezomib, busulfan, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cyclophosphamide, cytarabine (also known as arabinosylcytosine), cytarabine liposomal, dacarbazine, dactinomycin, daunorubicin liposomal, darbepoetin alfa, daunorubicin, decitabine, denileukin diftitox, dexamethasone (also known as dexamethasone sodium phosphate and dexamethasone acetate), dexrazoxane, docetaxel (e.g., Taxotere from Aventis S.A., Frankfurt, Germany), doxorubicin, doxorubicin hydrochloride (e.g., Adriamycin from Pharmacia & Upjohn, Peapack, N.J.), doxorubicin liposomal, epirubicin, epoetin alfa, estramustine, erlotinib, etoposide, exemestane, filgrastim, fluorouracil (also known as 5-fluorouracil), floxuridine, fludarabine, fluoxymesterone, flutamide, fulvestrant, gefitinib, gemcitabine, gemtuzumab, goserelin, ozogamicin, hydrocortisone (also known as cortisone), hydroxyurea, ibritumomab (also known as ibritumomab tiuxetan), idarubicin, ifosfamide, imatinib mesylate, irinotecan, lenalidomide, letrozole, leucovorin, leuprolide, lomustine, mechlorethamine (also known as nitrogen mustard, mustine, and mechlorethamine hydrochloride), megestrol (also known as megestrol acetate), melphalan, mercaptopurine (also known as 6-mercaptopurine), methotrexate (also known as amethopterin and methotrexate sodium), methylprednisolone, mesna, mitomycin (e.g., Mutamycin0 from Bristol-Myers Squibb Co., Stamford, Conn.), mitoxantrone, nelarabine, nilutamide, octreotide (also known as octreotide acetate), oprevelkin, oxaliplatin, paclitaxel (e.g., TAXOL by Bristol-Myers Squibb Co., Stamford, Conn.), paclitaxel protein-bound, pamidronate, peg interferon, pegaspargase, pegfilgrastim, pemetrexed, pentostatin, prednisolone, prednisone, procarbazine, raloxifene, rituximab, sargramostim, sorafenib, streptozocin, sunitinib, tamoxifen, temozolomide, teniposide, thalidomide, thiotepa (also known as thiophosphoamide), topotecan, toremifene, tositumomab (also known as iodine I ¨ 131), trastuzumab, vinblastine, vincristine, vinorelbine, and zoledronic acid.
Examples of such thrombolytics and/or fibrinolytics include tissue plasminogen activator (tPA), recombinant tPA, urokinase, streptokinase, tenecteplase, alteplase (e.g.
Activase from Genentech, Inc., San Francisco, CA), lysatec, antistreplase (e.g.
Eminaseg from Wulfing Pharma Gmbh, Germany), reteplase (e.g. Retavaseg from Centocor, Inc., Malvern, PA), hannahpep (Indian King Cobra venom), ancrod (Malayan pit viper venom), and matrix metalloproteinases, such as collagenase.
A second embodiment of the drug-eluting marker is shown in FIG. 7 in which like elements are designated with the same number bearing a prime (') symbol. The marker 60' can be comprised of a material 70 containing any of the drugs listed above. In this embodiment, the marker is made of a bioabsorbable material that will dissolve within the body at a predetermined rate, thus releasing the drug in a timed release fashion. Examples of such bioabsorbable materials are collagen, regenerated cellulose, synthetic polymers, and synthetic proteins.
A third embodiment of the drug-eluting marker is shown in FIG. 8 in which like elements are designated with the same number bearing a double-prime (") symbol. The marker 60" encapsulates, either fully or partially, the drug 64". For illustrative purposes, the marker 60" is shown as a hollow tube 72, made of any of the materials listed above, that encapsulates the drug 64". Multiple pores 76 extend fully through the tube 72 to allow the drug 64" to pass through the exterior of the marker 60". The drug 64" can also pass through the open ends of the tube 72. The tube 72 can alternately be solid with pores 76, extending only partially through the tube, designed to hold the drug 64".
In an alternate design of the third embodiment shown in FIG. 9, where like elements are designated with the same number bearing a triple-prime ("1) symbol, the marker 60" can embody a spring-like configuration 82 that fully or partially encapsulates the drug 64". The marker 60" can further be made of a bioabsorbable material, as discussed above, that either fully or partially encapsulated the drug 64".
As in the foregoing example, the marking apparatus 10 can be used to place a marker at the location of a tissue biopsy. However, the drug-eluting marker 60 can be used even if a biopsy has not been done. The drug-eluting marker 60 can be used as part of a treatment regimen whereby the drug 64 is delivered at a specific site within the body where the marker 60 is placed. For example, the marker 60 can be placed at a lesion detected using an imagining technique to mark the site prior to chemotherapy.
The imageability of the marker 60 allows the lesion to be tracked during chemotherapy since the lesion often disappears during treatment. The drug-eluting capability of the marker 60 allows a suitable drug 64 to be delivered to the lesion as part of the treatment.
While the invention has been specifically described in connection with certain specific embodiments thereof, it is to be understood that this is by way of illustration and not of limitation, and the scope of the appended claims should be construed as broadly as the prior art will permit.
A second embodiment of the drug-eluting marker is shown in FIG. 7 in which like elements are designated with the same number bearing a prime (') symbol. The marker 60' can be comprised of a material 70 containing any of the drugs listed above. In this embodiment, the marker is made of a bioabsorbable material that will dissolve within the body at a predetermined rate, thus releasing the drug in a timed release fashion. Examples of such bioabsorbable materials are collagen, regenerated cellulose, synthetic polymers, and synthetic proteins.
A third embodiment of the drug-eluting marker is shown in FIG. 8 in which like elements are designated with the same number bearing a double-prime (") symbol. The marker 60" encapsulates, either fully or partially, the drug 64". For illustrative purposes, the marker 60" is shown as a hollow tube 72, made of any of the materials listed above, that encapsulates the drug 64". Multiple pores 76 extend fully through the tube 72 to allow the drug 64" to pass through the exterior of the marker 60". The drug 64" can also pass through the open ends of the tube 72. The tube 72 can alternately be solid with pores 76, extending only partially through the tube, designed to hold the drug 64".
In an alternate design of the third embodiment shown in FIG. 9, where like elements are designated with the same number bearing a triple-prime ("1) symbol, the marker 60" can embody a spring-like configuration 82 that fully or partially encapsulates the drug 64". The marker 60" can further be made of a bioabsorbable material, as discussed above, that either fully or partially encapsulated the drug 64".
As in the foregoing example, the marking apparatus 10 can be used to place a marker at the location of a tissue biopsy. However, the drug-eluting marker 60 can be used even if a biopsy has not been done. The drug-eluting marker 60 can be used as part of a treatment regimen whereby the drug 64 is delivered at a specific site within the body where the marker 60 is placed. For example, the marker 60 can be placed at a lesion detected using an imagining technique to mark the site prior to chemotherapy.
The imageability of the marker 60 allows the lesion to be tracked during chemotherapy since the lesion often disappears during treatment. The drug-eluting capability of the marker 60 allows a suitable drug 64 to be delivered to the lesion as part of the treatment.
While the invention has been specifically described in connection with certain specific embodiments thereof, it is to be understood that this is by way of illustration and not of limitation, and the scope of the appended claims should be construed as broadly as the prior art will permit.
Claims (48)
1. A tissue marker, comprising:
a marker portion configured to mark a site within a soft tissue mass, the marker portion having a length extending along a centerline of the marker portion between a first end and a second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior; and a drug-eluting portion comprising a drug, wherein the drug-eluting portion is disposed within the hollow interior;
wherein the length of the marker portion is greater than an average diameter of the hollow interior and wherein the substantially continuous wall includes at least one opening adapted to allow the drug to pass out of the hollow interior.
a marker portion configured to mark a site within a soft tissue mass, the marker portion having a length extending along a centerline of the marker portion between a first end and a second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior; and a drug-eluting portion comprising a drug, wherein the drug-eluting portion is disposed within the hollow interior;
wherein the length of the marker portion is greater than an average diameter of the hollow interior and wherein the substantially continuous wall includes at least one opening adapted to allow the drug to pass out of the hollow interior.
2. The tissue marker according to claim 1, wherein the marker portion has a maximum length of 10 mm.
3. The tissue marker according to claim 1, wherein the site comprises a lesion and the marker portion is configured to mark a lesion having an effective size of at least 2 mm.
4. The tissue marker according to claim 1, wherein at least one of the marker portion and the drug eluting portion is imageable.
5. The tissue marker according to claim 4, wherein the marker portion is imageable.
6. The tissue marker according to claim 1, wherein the marker portion comprises a structure that resists migration of the tissue marker from the site.
7. The tissue marker according to claim 6, wherein the structure includes an anchor.
8. The tissue marker according to claim 1, wherein the marker portion comprises a substrate and the drug-eluting portion comprises a coating on the substrate.
9. The tissue marker according to claim 1, wherein the drug-eluting portion is embedded in the marker portion.
10. The tissue marker according to claim 9, wherein the marker portion is bioabsorbable.
11. The tissue marker according to claim 10, wherein the marker portion is configured to dissolve within the soft tissue mass at a predetermined rate and release the drug in a timed release fashion.
12. The tissue marker according to claim 1, wherein the marker portion comprises a spring.
13. The tissue marker according to claim 1, wherein the at least one opening comprises a plurality of pores.
14. The tissue marker according to claim 1, wherein the site includes a lesion or a biopsy site.
15. The tissue marker according to claim 1, wherein the drug includes an anti-inflammatory, antiplatelet, anticoagulant, antifebrin, antithrombin, cytostatic, antiproliferative, antibiotic, antimicrobial, antioxidant, antiallergic, antitumor, chemotherapeutic, antineoplastic, antimitotic, thrombolytic, fibrinolytic, vasodilator, antiviral, antihypertensive, antisecretory, immunosuppressive, growth factor, growth factor antagonist; antipolymerase, photodynamic therapy, antibody targeted therapy, prodrug, sex hormone, free radical scavengers, radiotherapeutic, radiopaque, radiolabelled, peptides, proteins, and enzyme substance, or any combination thereof.
16. The tissue marker according to claim 1, wherein the marker portion is non-prosthetic.
17. An imaging marker comprising:
a marker portion and a drug-eluting portion comprising a drug, with the marker portion, the drug-eluting portion, or both, being imageable, the marker portion having a length extending along a centerline of the marker portion between a first end and a second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior and at least partially encapsulating the drug eluting portion within the hollow interior, and wherein the length of the marker portion is greater than an average diameter of the hollow interior and the substantially continuous wall includes at least one opening adapted to allow the drug to pass out of the hollow interior.
a marker portion and a drug-eluting portion comprising a drug, with the marker portion, the drug-eluting portion, or both, being imageable, the marker portion having a length extending along a centerline of the marker portion between a first end and a second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior and at least partially encapsulating the drug eluting portion within the hollow interior, and wherein the length of the marker portion is greater than an average diameter of the hollow interior and the substantially continuous wall includes at least one opening adapted to allow the drug to pass out of the hollow interior.
18. The imaging marker according to claim 17, wherein the marker portion comprises an imageable substrate and the drug-eluting portion comprises a coating containing the drug applied to the substrate.
19. The imaging marker according to claim 17, wherein the marker portion comprises a substrate of bioabsorbable material containing the drug.
20. The imaging marker according to claim 17, wherein the at least one of the marker portion and the drug-eluting portion is non-prosthetic.
21. Use of a marker for marking a site within a soft tissue mass, wherein the marker has a length extending along a centerline of the marker between a first end and a second end and has a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior and at least partially encapsulating a drug within the hollow interior, and wherein the length of the marker is greater than an average diameter of the hollow interior and the substantially continuous wall includes at least one opening adapted to allow the drug to pass out of the hollow interior; and eluting the drug from the marker and wherein the marker is suitable for placement into a soft tissue mass.
22. The use according to claim 21, wherein the marker is suitable for placement at a lesion within the soft tissue mass.
23. The use according to claim 21, wherein the marker is suitable for placement at a site of a biopsy within the soft tissue mass.
24. The use method according to claim 21, wherein the marker is adapted to be localized by palpation of the soft tissue mass and by imaging of the soft tissue mass.
25. A tissue marker, comprising:
a marker portion configured to mark a site within a soft tissue mass, the marker portion being formed as a body having open ends, and having a substantially continuous wall bounding a hollow interior; and a drug-eluting portion comprising a drug, wherein the drug-eluting portion is disposed within the hollow interior of the body, and wherein the open ends facilitate a passing of the drug out of the hollow interior of the body to a region outside the body; and wherein the body is in the form of a tube having a plurality of openings that extend through the wall, and wherein the plurality of openings facilitate the passing of the drug out of the hollow interior of the tube to the region outside the tube.
a marker portion configured to mark a site within a soft tissue mass, the marker portion being formed as a body having open ends, and having a substantially continuous wall bounding a hollow interior; and a drug-eluting portion comprising a drug, wherein the drug-eluting portion is disposed within the hollow interior of the body, and wherein the open ends facilitate a passing of the drug out of the hollow interior of the body to a region outside the body; and wherein the body is in the form of a tube having a plurality of openings that extend through the wall, and wherein the plurality of openings facilitate the passing of the drug out of the hollow interior of the tube to the region outside the tube.
26. A tissue marking apparatus, comprising:
a marker introducer that includes a cannula and a stylet, the cannula having a lumen and a marker exit port, and the stylet being slidably received in the lumen, the stylet having a distal end; and a tissue marker configured to be received in the lumen distal to the distal end of the stylet, the tissue marker including:
a marker portion configured to mark a site within a soft tissue mass, the marker portion having a length extending along a centerline of the marker portion between a first end and a second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior; and a drug-eluting portion comprising a drug, wherein the substantially continuous wall that bounds the hollow interior includes at least one opening configured to allow the drug to pass out of the hollow interior.
a marker introducer that includes a cannula and a stylet, the cannula having a lumen and a marker exit port, and the stylet being slidably received in the lumen, the stylet having a distal end; and a tissue marker configured to be received in the lumen distal to the distal end of the stylet, the tissue marker including:
a marker portion configured to mark a site within a soft tissue mass, the marker portion having a length extending along a centerline of the marker portion between a first end and a second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior; and a drug-eluting portion comprising a drug, wherein the substantially continuous wall that bounds the hollow interior includes at least one opening configured to allow the drug to pass out of the hollow interior.
27. The tissue marking apparatus according to claim 26, wherein the at least one opening comprises a plurality of pores.
28. The tissue marking apparatus according to claim 26, wherein the marker portion comprises a structure that resists migration of the tissue marker from a tissue site.
29. The tissue marking apparatus according to claim 28, wherein the structure includes an anchor.
30. The tissue marking apparatus according to claim 26, wherein the marker portion comprises a substrate and the drug-eluting portion comprises a coating on the substrate.
31. The tissue marking apparatus according to claim 26, wherein the marker portion is configured to dissolve at a predetermined rate.
32. The tissue marking apparatus according to claim 26, wherein at least one of the marker portion and the drug eluting portion is formed from an imageable material.
33. The tissue marking apparatus according to claim 26, wherein the drug includes at least one of an anti-inflammatory, antiplatelet, anticoagulant, antifebrin, antithrombin, cytostatic, antiproliferative, antibiotic, antimicrobial, antioxidant, antiallergic, antitumor, chemotherapeutic, antineoplastic, antimitotic, thrombolytic, fibrinolytic, vasodilator, antiviral, antihypertensive, antisecretory, immunosuppressive, growth factor, growth factor antagonist; antipolymerase, photodynamic therapy, antibody targeted therapy, prodrug, sex hormone, free radical scavengers, radiotherapeutic, radiopaque, radiolabelled, peptides, proteins, and enzyme substance.
34. The tissue marking apparatus according to claim 26, wherein the marker portion is non-prosthetic.
35. A tissue marking apparatus, comprising:
a marker introducer that includes a cannula and a stylet, the cannula having a lumen and a marker exit port, and the stylet being slidably received in the lumen, the stylet having a distal end; and an imaging marker configured to be received in the lumen distal to the distal end of the stylet, the imaging marker including a marker portion and a drug-eluting portion, with at least one of the marker portion and the drug-eluting portion being imageable, the marker portion having a length extending along a centerline of the marker portion between a first end and a second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior and at least partially encapsulating the drug eluting portion within the hollow interior, and wherein the length of the marker portion is greater than an average diameter of the hollow interior and the substantially continuous wall includes at least one opening adapted to allow the drug to pass out of the hollow interior.
a marker introducer that includes a cannula and a stylet, the cannula having a lumen and a marker exit port, and the stylet being slidably received in the lumen, the stylet having a distal end; and an imaging marker configured to be received in the lumen distal to the distal end of the stylet, the imaging marker including a marker portion and a drug-eluting portion, with at least one of the marker portion and the drug-eluting portion being imageable, the marker portion having a length extending along a centerline of the marker portion between a first end and a second end and having a substantially continuous wall along the length, the substantially continuous wall bounding a hollow interior and at least partially encapsulating the drug eluting portion within the hollow interior, and wherein the length of the marker portion is greater than an average diameter of the hollow interior and the substantially continuous wall includes at least one opening adapted to allow the drug to pass out of the hollow interior.
36. The tissue marking apparatus according to claim 35, wherein the at least 5 opening comprises a plurality of pores.
37. The tissue marking apparatus according to claim 35, wherein the marker portion comprises an imageable substrate and the drug-eluting portion comprises a coating containing the drug applied to the substrate.
38. The tissue marking apparatus according to claim 35, wherein the marker portion comprises a substrate of bioabsorbable material containing the drug.
39. A tissue marking apparatus, comprising:
a marker introducer that includes a cannula and a stylet, the cannula having a lumen and a marker exit port, and the stylet being slidably received in the lumen, the stylet having a distal end; and a tissue marker configured to be received in the lumen distal to the distal end of the stylet, the tissue marker including:
a marker portion configured to mark a site within a soft tissue mass, the marker portion being formed as a body having open ends, and having a substantially continuous wall bounding a hollow interior;
and a drug-eluting portion comprising a drug, wherein the drug-eluting portion is disposed within the hollow interior of the body, and wherein the open ends facilitate a passing of the drug out of the hollow interior of the body to a region outside the body; and wherein the body is in the form of a tube having a plurality of openings that extend through the wall, and wherein the plurality of openings facilitate the passing of the drug out of the hollow interior of the tube to the region outside the tube.
a marker introducer that includes a cannula and a stylet, the cannula having a lumen and a marker exit port, and the stylet being slidably received in the lumen, the stylet having a distal end; and a tissue marker configured to be received in the lumen distal to the distal end of the stylet, the tissue marker including:
a marker portion configured to mark a site within a soft tissue mass, the marker portion being formed as a body having open ends, and having a substantially continuous wall bounding a hollow interior;
and a drug-eluting portion comprising a drug, wherein the drug-eluting portion is disposed within the hollow interior of the body, and wherein the open ends facilitate a passing of the drug out of the hollow interior of the body to a region outside the body; and wherein the body is in the form of a tube having a plurality of openings that extend through the wall, and wherein the plurality of openings facilitate the passing of the drug out of the hollow interior of the tube to the region outside the tube.
40. The tissue marking apparatus of claim 39, wherein the marker portion is non-prosthetic.
41. The tissue marking apparatus of claim 39, wherein the marker portion comprises a structure that resists migration of the tissue marker from a tissue site.
42. The tissue marking apparatus of claim 41, wherein the structure includes an anchor.
43. The tissue marking apparatus of claim 39, wherein the marker portion comprises a substrate and the drug-eluting portion comprises a coating on the substrate.
44. The tissue marking apparatus of claim 39, wherein the marker portion is configured to dissolve at a predetermined rate.
45. The tissue marking apparatus of claim 39, wherein at least one of the marker portion and the drug eluting portion is formed from an imageable material.
46. Use of the tissue marking apparatus according to any one of claims 1 to 16, for marking a site within a soft tissue mass.
47. The use according to claim 46, wherein the marker is suitable for placement at a lesion within the soft tissue mass.
48. The use according to claim 46 or 47, wherein the marker is suitable for placement at a site of biopsy within the soft tissue mass.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59663605P | 2005-10-07 | 2005-10-07 | |
US60/596,636 | 2005-10-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2562580A1 CA2562580A1 (en) | 2007-04-07 |
CA2562580C true CA2562580C (en) | 2014-04-29 |
Family
ID=37682705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2562580A Active CA2562580C (en) | 2005-10-07 | 2006-10-05 | Drug-eluting tissue marker |
Country Status (4)
Country | Link |
---|---|
US (2) | US8052658B2 (en) |
EP (1) | EP1772111B1 (en) |
CA (1) | CA2562580C (en) |
ES (1) | ES2558979T3 (en) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7651505B2 (en) | 2002-06-17 | 2010-01-26 | Senorx, Inc. | Plugged tip delivery for marker placement |
US8361082B2 (en) | 1999-02-02 | 2013-01-29 | Senorx, Inc. | Marker delivery device with releasable plug |
US8498693B2 (en) | 1999-02-02 | 2013-07-30 | Senorx, Inc. | Intracorporeal marker and marker delivery device |
US9820824B2 (en) | 1999-02-02 | 2017-11-21 | Senorx, Inc. | Deployment of polysaccharide markers for treating a site within a patent |
US20090030309A1 (en) | 2007-07-26 | 2009-01-29 | Senorx, Inc. | Deployment of polysaccharide markers |
US6575991B1 (en) | 1999-06-17 | 2003-06-10 | Inrad, Inc. | Apparatus for the percutaneous marking of a lesion |
US20060036158A1 (en) | 2003-11-17 | 2006-02-16 | Inrad, Inc. | Self-contained, self-piercing, side-expelling marking apparatus |
US20050273002A1 (en) | 2004-06-04 | 2005-12-08 | Goosen Ryan L | Multi-mode imaging marker |
US8419656B2 (en) | 2004-11-22 | 2013-04-16 | Bard Peripheral Vascular, Inc. | Post decompression marker introducer system |
US10357328B2 (en) | 2005-04-20 | 2019-07-23 | Bard Peripheral Vascular, Inc. and Bard Shannon Limited | Marking device with retractable cannula |
US8052658B2 (en) * | 2005-10-07 | 2011-11-08 | Bard Peripheral Vascular, Inc. | Drug-eluting tissue marker |
US11241296B2 (en) | 2005-11-17 | 2022-02-08 | Breast-Med, Inc. | Imaging fiducial markers and methods |
US7702378B2 (en) | 2005-11-17 | 2010-04-20 | Breast-Med, Inc. | Tissue marker for multimodality radiographic imaging |
ES2443526T3 (en) | 2006-10-23 | 2014-02-19 | C.R. Bard, Inc. | Breast marker |
EP2109409B1 (en) | 2006-12-12 | 2018-09-05 | C.R.Bard, Inc. | Multiple imaging mode tissue marker |
US8401622B2 (en) | 2006-12-18 | 2013-03-19 | C. R. Bard, Inc. | Biopsy marker with in situ-generated imaging properties |
US9375287B2 (en) * | 2008-01-29 | 2016-06-28 | Covidien Lp | Target identification tool for intra-body localization |
WO2009099767A2 (en) | 2008-01-31 | 2009-08-13 | C.R. Bard, Inc. | Biopsy tissue marker |
US9327061B2 (en) | 2008-09-23 | 2016-05-03 | Senorx, Inc. | Porous bioabsorbable implant |
AU2008365906B2 (en) | 2008-12-30 | 2015-01-22 | C.R. Bard Inc. | Marker delivery device for tissue marker placement |
US9936892B1 (en) | 2009-05-04 | 2018-04-10 | Cortex Manufacturing Inc. | Systems and methods for providing a fiducial marker |
US9014787B2 (en) | 2009-06-01 | 2015-04-21 | Focal Therapeutics, Inc. | Bioabsorbable target for diagnostic or therapeutic procedure |
CA2835412A1 (en) * | 2011-05-11 | 2012-11-15 | The Regents Of The University Of California | Fiduciary markers and methods of placement |
US20130289389A1 (en) | 2012-04-26 | 2013-10-31 | Focal Therapeutics | Surgical implant for marking soft tissue |
BR112015022057B1 (en) * | 2013-03-11 | 2022-06-28 | University Of Utah Research Foundation | SENSOR SYSTEMS |
USD716451S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD715442S1 (en) | 2013-09-24 | 2014-10-14 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD716450S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD715942S1 (en) | 2013-09-24 | 2014-10-21 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
AU2015292332A1 (en) | 2014-07-25 | 2017-02-16 | Focal Therapeutics, Inc. | Implantable devices and techniques for oncoplastic surgery |
US9795455B2 (en) | 2014-08-22 | 2017-10-24 | Breast-Med, Inc. | Tissue marker for multimodality radiographic imaging |
EP3248024B1 (en) * | 2015-01-21 | 2024-04-03 | Koninklijke Philips N.V. | Automated impedance adjustment of a multichannel rf coil assembly |
CN106730420A (en) * | 2017-02-06 | 2017-05-31 | 中国人民解放军总医院 | Tumor marker device |
US11219502B2 (en) | 2017-09-11 | 2022-01-11 | Medtronic Advanced Energy, Llc | Transformative shape-memory polymer tissue cavity marker devices, systems and deployment methods |
US11324567B2 (en) | 2018-02-01 | 2022-05-10 | Medtronic Advanced Energy, Llc | Expandable tissue cavity marker devices, systems and deployment methods |
WO2020227540A1 (en) | 2019-05-08 | 2020-11-12 | Atricure, Inc. | Biological tissue position location and marking |
Family Cites Families (455)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2899362A (en) | 1959-08-11 | Hemostatic sponges and method of | ||
US2192270A (en) | 1938-05-25 | 1940-03-05 | American Brake Co | Brake rigging |
US2481408A (en) | 1946-08-13 | 1949-09-06 | Olin Mathieson | Regeneration of caustic soda-sodium sulfide cooking liquor |
GB708148A (en) | 1950-12-18 | 1954-04-28 | Hoechst Ag | Hemostatic preparations and process for the manufacture thereof |
DE1029528B (en) | 1954-01-30 | 1958-05-08 | Med H C Ernst Pohl Dr | Device for marking a drill hole to be made, especially for bone nails and bone screws |
US2832888A (en) | 1956-05-17 | 1958-04-29 | David R Houston | Box car detector |
US2907327A (en) | 1957-02-08 | 1959-10-06 | Pfizer & Co C | Pellet implanter |
US3341417A (en) | 1965-07-14 | 1967-09-12 | Edwin S Sinaiko | Method of and means for diagnosis of ingested drugs with radio-opaque and other indicators |
US3516412A (en) | 1965-08-16 | 1970-06-23 | Electro Catheter Corp | Bipolar electrode having irregularity at inserting end thereof and method of insertion |
US3402712A (en) | 1966-07-19 | 1968-09-24 | American Home Prod | Pellet implanter |
US3593343A (en) | 1968-07-19 | 1971-07-20 | Robert F Viggers | Prosthetic ball-check heart valve |
US3823212A (en) | 1968-11-27 | 1974-07-09 | Freudenberg C Fa | Process for the production of collagen fiber fabrics in the form of felt-like membranes or sponge-like layers |
CS151338B1 (en) | 1971-01-22 | 1973-10-19 | ||
US3757781A (en) | 1971-09-17 | 1973-09-11 | R Smart | Tool for administering pills to animals |
US3921632A (en) | 1974-08-16 | 1975-11-25 | Frank M Bardani | Implant device |
US4005699A (en) | 1974-10-09 | 1977-02-01 | Louis Bucalo | Methods and apparatus for use in magnetic treatment of the body |
US4197846A (en) | 1974-10-09 | 1980-04-15 | Louis Bucalo | Method for structure for situating in a living body agents for treating the body |
US4007732A (en) | 1975-09-02 | 1977-02-15 | Robert Carl Kvavle | Method for location and removal of soft tissue in human biopsy operations |
US4041931A (en) | 1976-05-17 | 1977-08-16 | Elliott Donald P | Radiopaque anastomosis marker |
US4217889A (en) | 1976-09-15 | 1980-08-19 | Heyer-Schulte Corporation | Flap development device and method of progressively increasing skin area |
US4105030A (en) | 1977-01-03 | 1978-08-08 | Syntex (U.S.A.) Inc. | Implant apparatus |
US4103690A (en) | 1977-03-21 | 1978-08-01 | Cordis Corporation | Self-suturing cardiac pacer lead |
US4294241A (en) | 1977-06-09 | 1981-10-13 | Teruo Miyata | Collagen skin dressing |
US4588395A (en) | 1978-03-10 | 1986-05-13 | Lemelson Jerome H | Catheter and method |
US4172449A (en) | 1978-05-01 | 1979-10-30 | New Research And Development Laboratories, Inc. | Body fluid pressure monitor |
US4276885A (en) | 1979-05-04 | 1981-07-07 | Rasor Associates, Inc | Ultrasonic image enhancement |
US4331654A (en) | 1980-06-13 | 1982-05-25 | Eli Lilly And Company | Magnetically-localizable, biodegradable lipid microspheres |
US4390018A (en) | 1980-09-15 | 1983-06-28 | Zukowski Henry J | Method for preventing loss of spinal fluid after spinal tap |
US4442843A (en) | 1980-11-17 | 1984-04-17 | Schering, Ag | Microbubble precursors and methods for their production and use |
US4470160A (en) | 1980-11-21 | 1984-09-11 | Cavon Joseph F | Cast gel implantable prosthesis |
US4740208A (en) | 1980-11-21 | 1988-04-26 | Cavon Joseph F | Cast gel implantable prosthesis |
US4428082A (en) | 1980-12-08 | 1984-01-31 | Naficy Sadeque S | Breast prosthesis with filling valve |
US4298998A (en) | 1980-12-08 | 1981-11-10 | Naficy Sadeque S | Breast prosthesis with biologically absorbable outer container |
US4487209A (en) | 1981-03-16 | 1984-12-11 | Creative Research And Manufacturing Inc. | Biopsy needle |
US4401124A (en) | 1981-08-13 | 1983-08-30 | Technicare Corporation | Reflection enhancement of a biopsy needle |
US4400170A (en) | 1981-09-29 | 1983-08-23 | Syntex (U.S.A.) Inc. | Implanting device and implant magazine |
US4582061A (en) | 1981-11-18 | 1986-04-15 | Indianapolis Center For Advanced Research, Inc. | Needle with ultrasonically reflective displacement scale |
US4582640A (en) | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
US4405314A (en) | 1982-04-19 | 1983-09-20 | Cook Incorporated | Apparatus and method for catheterization permitting use of a smaller gage needle |
US4545367A (en) | 1982-07-16 | 1985-10-08 | Cordis Corporation | Detachable balloon catheter and method of use |
US5542915A (en) | 1992-08-12 | 1996-08-06 | Vidamed, Inc. | Thermal mapping catheter with ultrasound probe |
US4438253A (en) | 1982-11-12 | 1984-03-20 | American Cyanamid Company | Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same |
GB2138298B (en) | 1983-04-21 | 1986-11-05 | Hundon Forge Ltd | Pellet implanter |
US4647480A (en) | 1983-07-25 | 1987-03-03 | Amchem Products, Inc. | Use of additive in aqueous cure of autodeposited coatings |
US4655226A (en) | 1983-12-16 | 1987-04-07 | Southland Instruments, Inc. | Disposable biopsy needle unit |
CH661199A5 (en) | 1983-12-22 | 1987-07-15 | Sulzer Ag | MARKING IMPLANT. |
US4549560A (en) | 1984-03-19 | 1985-10-29 | Andis Company | Hair curling appliance with elastomer material covering heating element |
CA1295796C (en) | 1984-03-27 | 1992-02-18 | Conrad Whyne | Biodegradable matrix and methods for producing same |
US4648880A (en) | 1984-08-30 | 1987-03-10 | Daniel Brauman | Implantable prosthetic devices |
US4963150B1 (en) | 1984-08-30 | 1994-10-04 | Daniel Brauman | Implantable prosthetic device |
US4820267A (en) | 1985-02-19 | 1989-04-11 | Endocon, Inc. | Cartridge injector for pellet medicaments |
US4863470A (en) | 1985-03-19 | 1989-09-05 | Medical Engineering Corporation | Identification marker for a breast prosthesis |
US5628781A (en) | 1985-06-06 | 1997-05-13 | Thomas Jefferson University | Implant materials, methods of treating the surface of implants with microvascular endothelial cells, and the treated implants themselves |
US4847049A (en) | 1985-12-18 | 1989-07-11 | Vitaphore Corporation | Method of forming chelated collagen having bactericidal properties |
US4693237A (en) | 1986-01-21 | 1987-09-15 | Hoffman Richard B | Radiopaque coded ring markers for use in identifying surgical grafts |
US4682606A (en) | 1986-02-03 | 1987-07-28 | Decaprio Vincent H | Localizing biopsy apparatus |
US4661103A (en) | 1986-03-03 | 1987-04-28 | Engineering Development Associates, Ltd. | Multiple implant injector |
US4832686A (en) | 1986-06-24 | 1989-05-23 | Anderson Mark E | Method for administering interleukin-2 |
US4832680A (en) | 1986-07-03 | 1989-05-23 | C.R. Bard, Inc. | Apparatus for hypodermically implanting a genitourinary prosthesis |
ES2053019T3 (en) | 1986-07-30 | 1994-07-16 | Sumitomo Pharma | SOLID PREPARATION ADMINISTRATION INSTRUMENT. |
US4813062A (en) | 1986-08-13 | 1989-03-14 | Milliken Research Corporation | Radio-opaque marker and method |
US4762128A (en) | 1986-12-09 | 1988-08-09 | Advanced Surgical Intervention, Inc. | Method and apparatus for treating hypertrophy of the prostate gland |
US4994028A (en) | 1987-03-18 | 1991-02-19 | Endocon, Inc. | Injector for inplanting multiple pellet medicaments |
US4874376A (en) | 1987-04-13 | 1989-10-17 | Hawkins Jr Irvin F | Needle guide assembly |
ES2086291T3 (en) | 1987-05-26 | 1996-07-01 | Sumitomo Pharma | DEVICE FOR THE ADMINISTRATION OF SOLID PREPARATIONS. |
US4989608A (en) | 1987-07-02 | 1991-02-05 | Ratner Adam V | Device construction and method facilitating magnetic resonance imaging of foreign objects in a body |
US5120802A (en) | 1987-12-17 | 1992-06-09 | Allied-Signal Inc. | Polycarbonate-based block copolymers and devices |
US4889707A (en) | 1988-01-29 | 1989-12-26 | The Curators Of The University Of Missouri | Composition and method for radiation synovectomy of arthritic joints |
US4870966A (en) | 1988-02-01 | 1989-10-03 | American Cyanamid Company | Bioabsorbable surgical device for treating nerve defects |
IE66912B1 (en) | 1988-02-05 | 1996-02-07 | Schering Ag | Ultrasonic contrast agents process for their preparation and their use as diagnostic and therapeutic agents |
US5425366A (en) | 1988-02-05 | 1995-06-20 | Schering Aktiengesellschaft | Ultrasonic contrast agents for color Doppler imaging |
US5374261A (en) | 1990-07-24 | 1994-12-20 | Yoon; Inbae | Multifunctional devices for use in endoscopic surgical procedures and methods-therefor |
US4994013A (en) | 1988-07-28 | 1991-02-19 | Best Industries, Inc. | Pellet for a radioactive seed |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US4950665A (en) | 1988-10-28 | 1990-08-21 | Oklahoma Medical Research Foundation | Phototherapy using methylene blue |
US4909250A (en) | 1988-11-14 | 1990-03-20 | Smith Joseph R | Implant system for animal identification |
US5800541A (en) | 1988-11-21 | 1998-09-01 | Collagen Corporation | Collagen-synthetic polymer matrices prepared using a multiple step reaction |
US5162430A (en) | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US5475052A (en) | 1988-11-21 | 1995-12-12 | Collagen Corporation | Collagen-synthetic polymer matrices prepared using a multiple step reaction |
AU5154390A (en) | 1989-02-15 | 1990-09-05 | Microtek Medical, Inc. | Biocompatible material and prosthesis |
US5141748A (en) | 1989-02-17 | 1992-08-25 | Hoffmann-La Roche, Inc. | Implant drug delivery device |
US5289831A (en) | 1989-03-09 | 1994-03-01 | Vance Products Incorporated | Surface-treated stent, catheter, cannula, and the like |
US5081997A (en) | 1989-03-09 | 1992-01-21 | Vance Products Incorporated | Echogenic devices, material and method |
US5201314A (en) | 1989-03-09 | 1993-04-13 | Vance Products Incorporated | Echogenic devices, material and method |
US5025797A (en) | 1989-03-29 | 1991-06-25 | Baran Gregory W | Automated biopsy instrument |
GB2230191B (en) | 1989-04-15 | 1992-04-22 | Robert Graham Urie | Lesion location device |
DE8905585U1 (en) | 1989-05-03 | 1989-06-29 | Bosch-Siemens Hausgeraete Gmbh, 8000 Muenchen, De | |
US5012818A (en) | 1989-05-04 | 1991-05-07 | Joishy Suresh K | Two in one bone marrow surgical needle |
US5197482A (en) | 1989-06-15 | 1993-03-30 | Research Corporation Technologies, Inc. | Helical-tipped lesion localization needle device and method of using the same |
US5284479A (en) | 1989-08-30 | 1994-02-08 | N.V. Nederlandsche Apparatenfabriek Nedap | Implanter |
US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
JPH03158171A (en) | 1989-11-17 | 1991-07-08 | Masataka Saito | Cap integral type disposal injection needle |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5334381A (en) | 1989-12-22 | 1994-08-02 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5197846A (en) | 1989-12-22 | 1993-03-30 | Hitachi, Ltd. | Six-degree-of-freedom articulated robot mechanism and assembling and working apparatus using same |
GB9003821D0 (en) | 1990-02-20 | 1990-04-18 | Danbiosyst Uk | Diagnostic aid |
JPH042372U (en) | 1990-04-23 | 1992-01-09 | ||
US5137928A (en) | 1990-04-26 | 1992-08-11 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
AU636481B2 (en) | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
US5236410A (en) | 1990-08-02 | 1993-08-17 | Ferrotherm International, Inc. | Tumor treatment method |
DE69120177T2 (en) | 1990-09-10 | 1996-10-10 | Synthes Ag | Bone regeneration membrane |
US5353804A (en) | 1990-09-18 | 1994-10-11 | Peb Biopsy Corporation | Method and device for percutaneous exisional breast biopsy |
US5391183A (en) | 1990-09-21 | 1995-02-21 | Datascope Investment Corp | Device and method sealing puncture wounds |
US5221269A (en) | 1990-10-15 | 1993-06-22 | Cook Incorporated | Guide for localizing a nonpalpable breast lesion |
US6347240B1 (en) | 1990-10-19 | 2002-02-12 | St. Louis University | System and method for use in displaying images of a body part |
US5282781A (en) | 1990-10-25 | 1994-02-01 | Omnitron International Inc. | Source wire for localized radiation treatment of tumors |
US5370901A (en) | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
US5280788A (en) | 1991-02-26 | 1994-01-25 | Massachusetts Institute Of Technology | Devices and methods for optical diagnosis of tissue |
US5395319A (en) | 1991-03-06 | 1995-03-07 | Suddeutsche Feinmechanik Gmbh | Needle for inserting an object into the body |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
US5147631A (en) | 1991-04-30 | 1992-09-15 | Du Pont Merck Pharmaceutical Company | Porous inorganic ultrasound contrast agents |
US5354623A (en) | 1991-05-21 | 1994-10-11 | Cook Incorporated | Joint, a laminate, and a method of preparing a nickel-titanium alloy member surface for bonding to another layer of metal |
US5242759A (en) | 1991-05-21 | 1993-09-07 | Cook Incorporated | Joint, a laminate, and a method of preparing a nickel-titanium alloy member surface for bonding to another layer of metal |
US5147307A (en) | 1991-06-17 | 1992-09-15 | Gluck Seymour M | Anatomical marker device and method |
WO1993000933A1 (en) | 1991-07-05 | 1993-01-21 | University Of Rochester | Ultrasmall non-aggregated porous particles entrapping gas-bubbles |
US5449560A (en) | 1991-07-05 | 1995-09-12 | Dow Corning S.A. | Composition suitable for glass laminate interlayer and laminate made therefrom |
US5195540A (en) | 1991-08-12 | 1993-03-23 | Samuel Shiber | Lesion marking process |
US5199441A (en) | 1991-08-20 | 1993-04-06 | Hogle Hugh H | Fine needle aspiration biopsy apparatus and method |
NL9101489A (en) | 1991-09-03 | 1993-04-01 | Texas Instruments Holland | INJECTOR FOR IMMEDIATELY IMPLANTING AN OBJECT IN A LIVING BEING. |
US5320100A (en) | 1991-09-16 | 1994-06-14 | Atrium Medical Corporation | Implantable prosthetic device having integral patency diagnostic indicia |
US5344640A (en) | 1991-10-22 | 1994-09-06 | Mallinckrodt Medical, Inc. | Preparation of apatite particles for medical diagnostic imaging |
US5358514A (en) | 1991-12-18 | 1994-10-25 | Alfred E. Mann Foundation For Scientific Research | Implantable microdevice with self-attaching electrodes |
GB9200391D0 (en) | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
FR2686499A1 (en) | 1992-01-28 | 1993-07-30 | Technomed Int Sa | APPARATUS FOR TREATING A TARGET, SUCH AS A DAMAGE WITHIN THE BODY OF A MAMMAL, PARTICULARLY A HUMAN BEING, USING A MARKING ELEMENT IMPLANTED IN OR IN THE VICINITY OF THE TARGET TO CONTROL THERAPY OF THE SAME TARGET. |
WO1993016735A1 (en) | 1992-02-28 | 1993-09-02 | Order Stanley E | Use of aggregated proteins to prolong retention time of a therapeutic agent adjacent a targeted site such as a tumor |
US5674468A (en) | 1992-03-06 | 1997-10-07 | Nycomed Imaging As | Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons |
PL174114B1 (en) | 1992-03-06 | 1998-06-30 | Nycomed Imaging As | Contrast medium |
DK0634927T3 (en) | 1992-03-06 | 2001-10-29 | Lica Pharmaceuticals As | Treatment and prophylaxis of diseases caused by parasites or bacteria |
US6350274B1 (en) | 1992-05-11 | 2002-02-26 | Regen Biologics, Inc. | Soft tissue closure systems |
NL9200844A (en) | 1992-05-13 | 1993-12-01 | De Wijdeven Gijsbertus G P Van | DEVICE AND METHOD FOR INJECTING WITH A SOLID SUBSTANCE. |
US5250026A (en) | 1992-05-27 | 1993-10-05 | Destron/Idi, Inc. | Adjustable precision transponder injector |
US5629008A (en) | 1992-06-02 | 1997-05-13 | C.R. Bard, Inc. | Method and device for long-term delivery of drugs |
US5366756A (en) | 1992-06-15 | 1994-11-22 | United States Surgical Corporation | Method for treating bioabsorbable implant material |
US5281197A (en) | 1992-07-27 | 1994-01-25 | Symbiosis Corporation | Endoscopic hemostatic agent delivery system |
US5469847A (en) | 1992-09-09 | 1995-11-28 | Izi Corporation | Radiographic multi-modality skin markers |
US5368030A (en) | 1992-09-09 | 1994-11-29 | Izi Corporation | Non-invasive multi-modality radiographic surface markers |
US5460182A (en) | 1992-09-14 | 1995-10-24 | Sextant Medical Corporation | Tissue penetrating apparatus and methods |
US5320613A (en) | 1993-01-06 | 1994-06-14 | Scimed Life Systems, Inc. | Medical lumen flushing and guide wire loading device and method |
EP0636015A4 (en) | 1993-01-19 | 1995-08-02 | Hang Fu Lee | Apparatus and method for implant prostheses. |
DK12293D0 (en) | 1993-02-02 | 1993-02-02 | Novo Nordisk As | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE |
US5551429A (en) | 1993-02-12 | 1996-09-03 | Fitzpatrick; J. Michael | Method for relating the data of an image space to physical space |
US5799099A (en) | 1993-02-12 | 1998-08-25 | George S. Allen | Automatic technique for localizing externally attached fiducial markers in volume images of the head |
US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
US5388588A (en) | 1993-05-04 | 1995-02-14 | Nabai; Hossein | Biopsy wound closure device and method |
US5409004A (en) | 1993-06-11 | 1995-04-25 | Cook Incorporated | Localization device with radiopaque markings |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US5431639A (en) | 1993-08-12 | 1995-07-11 | Boston Scientific Corporation | Treating wounds caused by medical procedures |
US5494030A (en) | 1993-08-12 | 1996-02-27 | Trustees Of Dartmouth College | Apparatus and methodology for determining oxygen in biological systems |
US5490521A (en) | 1993-08-31 | 1996-02-13 | Medtronic, Inc. | Ultrasound biopsy needle |
US5676698A (en) | 1993-09-07 | 1997-10-14 | Datascope Investment Corp. | Soft tissue implant |
US5394875A (en) | 1993-10-21 | 1995-03-07 | Lewis; Judith T. | Automatic ultrasonic localization of targets implanted in a portion of the anatomy |
US5433204A (en) | 1993-11-16 | 1995-07-18 | Camilla Olson | Method of assessing placentation |
US5728122A (en) | 1994-01-18 | 1998-03-17 | Datascope Investment Corp. | Guide wire with releaseable barb anchor |
US6241734B1 (en) | 1998-08-14 | 2001-06-05 | Kyphon, Inc. | Systems and methods for placing materials into bone |
US5626611A (en) | 1994-02-10 | 1997-05-06 | United States Surgical Corporation | Composite bioabsorbable materials and surgical articles made therefrom |
US5928773A (en) | 1994-02-15 | 1999-07-27 | Vitric Corporation | Foamed glass articles and methods of making same and methods of controlling the pH of same within specific limits |
US5507807A (en) | 1994-03-01 | 1996-04-16 | Shippert; Ronald D. | Apparatus for the release of a substance within a patient |
US5417708A (en) | 1994-03-09 | 1995-05-23 | Cook Incorporated | Intravascular treatment system and percutaneous release mechanism therefor |
US5422730A (en) | 1994-03-25 | 1995-06-06 | Barlow; Clyde H. | Automated optical detection of tissue perfusion by microspheres |
US5451406A (en) | 1994-07-14 | 1995-09-19 | Advanced Uroscience, Inc. | Tissue injectable composition and method of use |
US6159445A (en) | 1994-07-20 | 2000-12-12 | Nycomed Imaging As | Light imaging contrast agents |
CA2199864C (en) | 1994-09-16 | 2006-06-20 | Seth A. Foerster | Methods and devices for defining and marking tissue |
US5954670A (en) | 1994-10-05 | 1999-09-21 | Baker; Gary H. | Mandrel-guided tandem multiple channel biopsy guide device and method of use |
US5891558A (en) | 1994-11-22 | 1999-04-06 | Tissue Engineering, Inc. | Biopolymer foams for use in tissue repair and reconstruction |
US5632432A (en) | 1994-12-19 | 1997-05-27 | Ethicon Endo-Surgery, Inc. | Surgical instrument |
US5499989A (en) | 1994-12-22 | 1996-03-19 | Labash; Stephen S. | Breast biopsy apparatus and method of use |
US6540981B2 (en) | 1997-12-04 | 2003-04-01 | Amersham Health As | Light imaging contrast agents |
US5643246A (en) | 1995-02-24 | 1997-07-01 | Gel Sciences, Inc. | Electromagnetically triggered, responsive gel based drug delivery device |
FR2731343B1 (en) | 1995-03-08 | 1997-08-22 | De La Joliniere Jean H Bouquet | DEVICE FOR LOCATING SUSPECTED BREAST INJURIES AND APPARATUS FOR PLACING SAME |
US5795308A (en) | 1995-03-09 | 1998-08-18 | Russin; Lincoln D. | Apparatus for coaxial breast biopsy |
US5762903A (en) | 1995-03-10 | 1998-06-09 | Korea Atomic Energy Research Institute | Radioactive chitosan complex for radiation therapy |
US5817022A (en) | 1995-03-28 | 1998-10-06 | Sonometrics Corporation | System for displaying a 2-D ultrasound image within a 3-D viewing environment |
US6120536A (en) | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
GB2301362B (en) | 1995-05-30 | 1999-01-06 | Johnson & Johnson Medical | Absorbable implant materials having controlled porosity |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US5779647A (en) | 1995-06-07 | 1998-07-14 | Chau; Sonny | Automated biopsy instruments |
US5609629A (en) | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US5580568A (en) | 1995-07-27 | 1996-12-03 | Micro Therapeutics, Inc. | Cellulose diacetate compositions for use in embolizing blood vessels |
US5667767A (en) | 1995-07-27 | 1997-09-16 | Micro Therapeutics, Inc. | Compositions for use in embolizing blood vessels |
US5817034A (en) | 1995-09-08 | 1998-10-06 | United States Surgical Corporation | Apparatus and method for removing tissue |
US5611352A (en) | 1995-09-14 | 1997-03-18 | Kobren; Myles S. | Cervical biopsy device |
US6183497B1 (en) | 1998-05-01 | 2001-02-06 | Sub-Q, Inc. | Absorbable sponge with contrasting agent |
US6071301A (en) | 1998-05-01 | 2000-06-06 | Sub Q., Inc. | Device and method for facilitating hemostasis of a biopsy tract |
US6162192A (en) | 1998-05-01 | 2000-12-19 | Sub Q, Inc. | System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge |
WO1997013463A1 (en) | 1995-10-13 | 1997-04-17 | Transvascular, Inc. | Methods and apparatus for bypassing arterial obstructions and/or performing other transvascular procedures |
US5800445A (en) | 1995-10-20 | 1998-09-01 | United States Surgical Corporation | Tissue tagging device |
US5782775A (en) | 1995-10-20 | 1998-07-21 | United States Surgical Corporation | Apparatus and method for localizing and removing tissue |
CA2187975C (en) | 1995-10-20 | 2001-05-01 | Lisa W. Heaton | Surgical apparatus and method for marking tissue location |
US5782764A (en) | 1995-11-07 | 1998-07-21 | Iti Medical Technologies, Inc. | Fiber composite invasive medical instruments and methods for use in interventional imaging procedures |
US5769086A (en) | 1995-12-06 | 1998-06-23 | Biopsys Medical, Inc. | Control system and method for automated biopsy device |
US6203524B1 (en) | 1997-02-10 | 2001-03-20 | Emx, Inc. | Surgical and pharmaceutical site access guide and methods |
US5800389A (en) | 1996-02-09 | 1998-09-01 | Emx, Inc. | Biopsy device |
US5842477A (en) | 1996-02-21 | 1998-12-01 | Advanced Tissue Sciences, Inc. | Method for repairing cartilage |
US5636255A (en) | 1996-03-05 | 1997-06-03 | Queen's University At Kingston | Method and apparatus for CT image registration |
JP2000509014A (en) | 1996-03-11 | 2000-07-18 | フォーカル,インコーポレイテッド | Polymer delivery of radionuclides and radiopharmaceuticals |
US5747060A (en) | 1996-03-26 | 1998-05-05 | Euro-Celtique, S.A. | Prolonged local anesthesia with colchicine |
US5821184A (en) | 1996-03-29 | 1998-10-13 | Andrew Ungerleider | Foamed glass article for preparing surfaces, use therefor, and method of making same |
US5865806A (en) | 1996-04-04 | 1999-02-02 | Becton Dickinson And Company | One step catheter advancement automatic needle retraction system |
US5824042A (en) | 1996-04-05 | 1998-10-20 | Medtronic, Inc. | Endoluminal prostheses having position indicating markers |
US5669882A (en) | 1996-04-23 | 1997-09-23 | Pyles; Stephen | Curved epidural needle system |
US7236816B2 (en) | 1996-04-25 | 2007-06-26 | Johns Hopkins University | Biopsy and sampling needle antennas for magnetic resonance imaging-guided biopsies |
US5846220A (en) | 1996-04-30 | 1998-12-08 | Medtronic, Inc. | Therapeutic method for treatment of Alzheimer's disease |
US6530896B1 (en) | 1996-05-13 | 2003-03-11 | James B. Elliott | Apparatus and method for introducing an implant |
US5690120A (en) | 1996-05-24 | 1997-11-25 | Sarcos, Inc. | Hybrid catheter guide wire apparatus |
US5853366A (en) | 1996-07-08 | 1998-12-29 | Kelsey, Inc. | Marker element for interstitial treatment and localizing device and method using same |
US5820918A (en) | 1996-07-11 | 1998-10-13 | Hercules Incorporated | Medical devices containing in-situ generated medical compounds |
US5702128A (en) | 1996-07-18 | 1997-12-30 | Beekley Corporation | Radiographic marker system and method of making same |
US5695480A (en) | 1996-07-29 | 1997-12-09 | Micro Therapeutics, Inc. | Embolizing compositions |
US5830178A (en) | 1996-10-11 | 1998-11-03 | Micro Therapeutics, Inc. | Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide |
US5823198A (en) | 1996-07-31 | 1998-10-20 | Micro Therapeutics, Inc. | Method and apparatus for intravasculer embolization |
US5842999A (en) | 1996-07-31 | 1998-12-01 | C.R. Bard, Inc. | Automated tissue sampling device |
US5902310A (en) | 1996-08-12 | 1999-05-11 | Ethicon Endo-Surgery, Inc. | Apparatus and method for marking tissue |
US6066325A (en) | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US5676146B1 (en) | 1996-09-13 | 2000-04-18 | Osteotech Inc | Surgical implant containing a resorbable radiopaque marker and method of locating such within a body |
US5824081A (en) | 1996-09-13 | 1998-10-20 | Lipomatrix Incorporated | Hydraulic foam tissue implant |
CZ149499A3 (en) | 1996-10-28 | 1999-09-15 | Nycomed Imaging As | Diagnostic and/or therapeutic preparation |
US5845646A (en) | 1996-11-05 | 1998-12-08 | Lemelson; Jerome | System and method for treating select tissue in a living being |
US6106473A (en) | 1996-11-06 | 2000-08-22 | Sts Biopolymers, Inc. | Echogenic coatings |
US6119031A (en) | 1996-11-21 | 2000-09-12 | Boston Scientific Corporation | Miniature spectrometer |
US5897507A (en) | 1996-11-25 | 1999-04-27 | Symbiosis Corporation | Biopsy forceps instrument having irrigation and aspiration capabilities |
US5876340A (en) | 1997-04-17 | 1999-03-02 | Irvine Biomedical, Inc. | Ablation apparatus with ultrasonic imaging capabilities |
US5941439A (en) | 1997-05-14 | 1999-08-24 | Mitek Surgical Products, Inc. | Applicator and method for deploying a surgical fastener in tissue |
US5876457A (en) | 1997-05-20 | 1999-03-02 | George J. Picha | Spinal implant |
EP0989870A4 (en) | 1997-06-13 | 2000-08-30 | Micro Therapeutics Inc | Contoured syringe and novel luer hub and methods for embolizing blood vessels |
GB9712525D0 (en) | 1997-06-16 | 1997-08-20 | Nycomed Imaging As | Method |
US6306154B1 (en) | 1997-06-18 | 2001-10-23 | Bhk Holding | Hemostatic system for body cavities |
DE19731021A1 (en) | 1997-07-18 | 1999-01-21 | Meyer Joerg | In vivo degradable metallic implant |
US6096037A (en) | 1997-07-29 | 2000-08-01 | Medtronic, Inc. | Tissue sealing electrosurgery device and methods of sealing tissue |
US6096065A (en) | 1997-09-29 | 2000-08-01 | Boston Scientific Corporation | Sheath for tissue spectroscopy |
US6340367B1 (en) | 1997-08-01 | 2002-01-22 | Boston Scientific Scimed, Inc. | Radiopaque markers and methods of using the same |
US6174330B1 (en) | 1997-08-01 | 2001-01-16 | Schneider (Usa) Inc | Bioabsorbable marker having radiopaque constituents |
US5980564A (en) | 1997-08-01 | 1999-11-09 | Schneider (Usa) Inc. | Bioabsorbable implantable endoprosthesis with reservoir |
US6090996A (en) | 1997-08-04 | 2000-07-18 | Collagen Matrix, Inc. | Implant matrix |
EP1003422B1 (en) | 1997-08-05 | 2006-06-14 | Boston Scientific Limited | Detachable aneurysm neck bridge |
US5854382A (en) | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
US6316522B1 (en) | 1997-08-18 | 2001-11-13 | Scimed Life Systems, Inc. | Bioresorbable hydrogel compositions for implantable prostheses |
DE20103363U1 (en) | 2001-02-26 | 2001-05-17 | Braun Melsungen Ag | Protection device for an injection needle |
US6616630B1 (en) | 1997-08-20 | 2003-09-09 | B. Braun Melsungen A.G. | Spring clip safety IV catheter |
US6117108A (en) | 1997-08-20 | 2000-09-12 | Braun Melsungen Ag | Spring clip safety IV catheter |
US7125397B2 (en) | 1997-08-20 | 2006-10-24 | B. Braun Melsungen Ag | Protective device for an injection needle |
US6551253B2 (en) | 1997-09-12 | 2003-04-22 | Imagyn Medical Technologies | Incisional breast biopsy device |
US6142955A (en) | 1997-09-19 | 2000-11-07 | United States Surgical Corporation | Biopsy apparatus and method |
US6638308B2 (en) | 1997-10-10 | 2003-10-28 | John D. Corbitt, Jr. | Bioabsorbable breast implant |
JP2001519203A (en) | 1997-10-10 | 2001-10-23 | ジョン・ディ・コービット・ジュニア | Breast implant |
US7637948B2 (en) | 1997-10-10 | 2009-12-29 | Senorx, Inc. | Tissue marking implant |
US6309420B1 (en) | 1997-10-14 | 2001-10-30 | Parallax Medical, Inc. | Enhanced visibility materials for implantation in hard tissue |
US6511468B1 (en) | 1997-10-17 | 2003-01-28 | Micro Therapeutics, Inc. | Device and method for controlling injection of liquid embolic composition |
CA2318488A1 (en) | 1997-10-24 | 1999-05-06 | Children's Medical Center Corporation | Methods for promoting cell transfection in vivo |
US6030333A (en) | 1997-10-24 | 2000-02-29 | Radiomed Corporation | Implantable radiotherapy device |
US6015541A (en) | 1997-11-03 | 2000-01-18 | Micro Therapeutics, Inc. | Radioactive embolizing compositions |
US6270464B1 (en) | 1998-06-22 | 2001-08-07 | Artemis Medical, Inc. | Biopsy localization method and device |
US6251418B1 (en) | 1997-12-18 | 2001-06-26 | C.R. Bard, Inc. | Systems and methods for local delivery of an agent |
ES2216340T3 (en) | 1997-12-29 | 2004-10-16 | Alza Corporation | IMPLANTING DEVICE FOR SUBCUTANEOUS IMPLANTS. |
US6451871B1 (en) | 1998-11-25 | 2002-09-17 | Novartis Ag | Methods of modifying surface characteristics |
US6118848A (en) | 1998-01-14 | 2000-09-12 | Reiffel; Leonard | System to stabilize an irradiated internal target |
US6181960B1 (en) | 1998-01-15 | 2001-01-30 | University Of Virginia Patent Foundation | Biopsy marker device |
US6289229B1 (en) | 1998-01-20 | 2001-09-11 | Scimed Life Systems, Inc. | Readable probe array for in vivo use |
US6660010B2 (en) | 1998-01-27 | 2003-12-09 | Scimed Life Systems, Inc. | Bone anchor placement device with recessed anchor mount |
US6053925A (en) | 1998-02-27 | 2000-04-25 | Barnhart; William H. | Lesion localization device and method |
US6638234B2 (en) | 1998-03-03 | 2003-10-28 | Senorx, Inc. | Sentinel node location and biopsy |
US6312429B1 (en) | 1998-09-01 | 2001-11-06 | Senorx, Inc. | Electrosurgical lesion location device |
US6471700B1 (en) | 1998-04-08 | 2002-10-29 | Senorx, Inc. | Apparatus and method for accessing biopsy site |
DE69938898D1 (en) | 1998-04-07 | 2008-07-24 | Cytyc Corp | DEVICES FOR LOCATING LESIONS IN FIXED TISSUE |
US6161034A (en) | 1999-02-02 | 2000-12-12 | Senorx, Inc. | Methods and chemical preparations for time-limited marking of biopsy sites |
US6347241B2 (en) | 1999-02-02 | 2002-02-12 | Senorx, Inc. | Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it |
US6610026B2 (en) | 1998-05-01 | 2003-08-26 | Sub-Q, Inc. | Method of hydrating a sponge material for delivery to a body |
US20010045575A1 (en) | 1998-05-01 | 2001-11-29 | Mark Ashby | Device and method for facilitating hemostasis of a biopsy tract |
US6363940B1 (en) | 1998-05-14 | 2002-04-02 | Calypso Medical Technologies, Inc. | System and method for bracketing and removing tissue |
US6224630B1 (en) | 1998-05-29 | 2001-05-01 | Advanced Bio Surfaces, Inc. | Implantable tissue repair device |
US6159143A (en) | 1998-06-17 | 2000-12-12 | Scimed Life Systems, Inc. | Method and device for delivery of therapeutic agents in conjunction with isotope seed placement |
US20020058882A1 (en) | 1998-06-22 | 2002-05-16 | Artemis Medical, Incorporated | Biopsy localization method and device |
EP0966979B1 (en) | 1998-06-25 | 2006-03-08 | Biotronik AG | Implantable bioresorbable support for the vascular walls, in particular coronary stent |
US5941890A (en) | 1998-06-26 | 1999-08-24 | Ethicon Endo-Surgery, Inc. | Implantable surgical marker |
US6261302B1 (en) | 1998-06-26 | 2001-07-17 | Ethicon Endo-Surgery, Inc. | Applier for implantable surgical marker |
US5921933A (en) | 1998-08-17 | 1999-07-13 | Medtronic, Inc. | Medical devices with echogenic coatings |
US6179860B1 (en) | 1998-08-19 | 2001-01-30 | Artemis Medical, Inc. | Target tissue localization device and method |
IL141462A0 (en) | 1998-08-21 | 2002-03-10 | Providence Health Sys Oregon | Insertable stent and methods of making and using the same |
US6335029B1 (en) | 1998-08-28 | 2002-01-01 | Scimed Life Systems, Inc. | Polymeric coatings for controlled delivery of active agents |
US6159240A (en) | 1998-08-31 | 2000-12-12 | Medtronic, Inc. | Rigid annuloplasty device that becomes compliant after implantation |
US6936014B2 (en) | 2002-10-16 | 2005-08-30 | Rubicor Medical, Inc. | Devices and methods for performing procedures on a breast |
US6656192B2 (en) | 1998-09-25 | 2003-12-02 | United States Surgical Corporatioin | Site marker device |
US6056700A (en) | 1998-10-13 | 2000-05-02 | Emx, Inc. | Biopsy marker assembly and method of use |
EP0993843B1 (en) | 1998-10-14 | 2006-04-26 | Terumo Kabushiki Kaisha | Radiation source delivery wire and catheter assembly for radiation therapy |
US6220248B1 (en) | 1998-10-21 | 2001-04-24 | Ethicon Endo-Surgery, Inc. | Method for implanting a biopsy marker |
WO2000023124A1 (en) | 1998-10-22 | 2000-04-27 | Edwards Lifesciences Corporation | Multi-functional coatings for medical devices |
WO2000024332A1 (en) | 1998-10-23 | 2000-05-04 | Cortese Armand F | Marker for indicating the location of identified tissue |
US6951564B2 (en) | 1998-10-23 | 2005-10-04 | United States Surgical Corporation | Site marker device |
ES2259480T3 (en) | 1998-11-06 | 2006-10-01 | Ge Healthcare Limited | BRAQUITERAPIA PRODUCTS AND METHODS. |
US6371904B1 (en) * | 1998-12-24 | 2002-04-16 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US6356782B1 (en) | 1998-12-24 | 2002-03-12 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US6270472B1 (en) | 1998-12-29 | 2001-08-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Apparatus and a method for automatically introducing implants into soft tissue with adjustable spacing |
US7651505B2 (en) | 2002-06-17 | 2010-01-26 | Senorx, Inc. | Plugged tip delivery for marker placement |
US20090030309A1 (en) | 2007-07-26 | 2009-01-29 | Senorx, Inc. | Deployment of polysaccharide markers |
US20080039819A1 (en) | 2006-08-04 | 2008-02-14 | Senorx, Inc. | Marker formed of starch or other suitable polysaccharide |
US7983734B2 (en) | 2003-05-23 | 2011-07-19 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US6725083B1 (en) | 1999-02-02 | 2004-04-20 | Senorx, Inc. | Tissue site markers for in VIVO imaging |
US8282573B2 (en) | 2003-02-24 | 2012-10-09 | Senorx, Inc. | Biopsy device with selectable tissue receiving aperture orientation and site illumination |
US6862470B2 (en) | 1999-02-02 | 2005-03-01 | Senorx, Inc. | Cavity-filling biopsy site markers |
JP3720999B2 (en) | 1999-02-18 | 2005-11-30 | 沖電気工業株式会社 | Input protection circuit |
US6482143B1 (en) | 1999-02-28 | 2002-11-19 | Syntheon, Llc | Raidoactive therapeutic seed having selective marker configuration |
US6200258B1 (en) | 1999-08-10 | 2001-03-13 | Syntheon, Llc | Radioactive therapeutic seed having selective marker configuration |
US6173715B1 (en) | 1999-03-01 | 2001-01-16 | Lucent Medical Systems, Inc. | Magnetic anatomical marker and method of use |
US6144875A (en) | 1999-03-16 | 2000-11-07 | Accuray Incorporated | Apparatus and method for compensating for respiratory and patient motion during treatment |
US6712836B1 (en) | 1999-05-13 | 2004-03-30 | St. Jude Medical Atg, Inc. | Apparatus and methods for closing septal defects and occluding blood flow |
JP2003501127A (en) | 1999-06-05 | 2003-01-14 | ウイルソンークック メディカル インク. | Display for endoscopic medical devices |
US6066122A (en) | 1999-06-09 | 2000-05-23 | Fisher; John | Needle apparatus and method for marking lesions |
US6766186B1 (en) | 1999-06-16 | 2004-07-20 | C. R. Bard, Inc. | Post biospy tissue marker and method of use |
US6575991B1 (en) | 1999-06-17 | 2003-06-10 | Inrad, Inc. | Apparatus for the percutaneous marking of a lesion |
WO2001008578A1 (en) | 1999-07-30 | 2001-02-08 | Vivant Medical, Inc. | Device and method for safe location and marking of a cavity and sentinel lymph nodes |
US6234177B1 (en) | 1999-08-12 | 2001-05-22 | Thomas Barsch | Apparatus and method for deploying an expandable biopsy marker |
US6250307B1 (en) | 1999-09-17 | 2001-06-26 | Pi Medical, Inc. | Snoring treatment |
US8239001B2 (en) | 2003-10-17 | 2012-08-07 | Medtronic Navigation, Inc. | Method and apparatus for surgical navigation |
US6450937B1 (en) | 1999-12-17 | 2002-09-17 | C. R. Bard, Inc. | Needle for implanting brachytherapy seeds |
US6371804B1 (en) | 1999-12-21 | 2002-04-16 | Hon Hai Precision Ind. Co., Ltd. | Retention means for a cable connector assembly |
AU2623201A (en) | 1999-12-30 | 2001-07-16 | Kam W Leong | Controlled delivery of therapeutic agents by insertable medical devices |
EP1114618A3 (en) | 2000-01-04 | 2001-08-22 | Ethicon Endo-Surgery, Inc. | Surgical instrument for applying beads to tissue |
US6506156B1 (en) | 2000-01-19 | 2003-01-14 | Vascular Control Systems, Inc | Echogenic coating |
US6575888B2 (en) | 2000-01-25 | 2003-06-10 | Biosurface Engineering Technologies, Inc. | Bioabsorbable brachytherapy device |
US6358217B1 (en) | 2000-01-31 | 2002-03-19 | Hugh Bourassa | Automatic and semi-automatic disposable biopsy needle device |
US6436030B2 (en) | 2000-01-31 | 2002-08-20 | Om P. Rehil | Hiatal hernia repair patch and method for using the same |
US6241687B1 (en) | 2000-02-18 | 2001-06-05 | Ethicon Endo-Surgery, Inc. | Method of use for a biopsy instrument with breakable sample segments |
JP5090600B2 (en) | 2000-02-18 | 2012-12-05 | トーマス ジェイ. フォガーティー, | Improved device for accurately marking tissues |
US6564806B1 (en) | 2000-02-18 | 2003-05-20 | Thomas J. Fogarty | Device for accurately marking tissue |
US6350244B1 (en) * | 2000-02-21 | 2002-02-26 | Biopsy Sciences, Llc | Bioabsorable markers for use in biopsy procedures |
US6770070B1 (en) | 2000-03-17 | 2004-08-03 | Rita Medical Systems, Inc. | Lung treatment apparatus and method |
US6450938B1 (en) | 2000-03-21 | 2002-09-17 | Promex, Llc | Brachytherapy device |
US6356112B1 (en) | 2000-03-28 | 2002-03-12 | Translogic Technology, Inc. | Exclusive or/nor circuit |
US6628982B1 (en) | 2000-03-30 | 2003-09-30 | The Regents Of The University Of Michigan | Internal marker device for identification of biological substances |
AU2001251134B2 (en) | 2000-03-31 | 2006-02-02 | Angiodynamics, Inc. | Tissue biopsy and treatment apparatus and method |
US6425903B1 (en) | 2000-05-09 | 2002-07-30 | James W. Voegele | Implantable surgical marker |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US7419678B2 (en) | 2000-05-12 | 2008-09-02 | Cordis Corporation | Coated medical devices for the prevention and treatment of vascular disease |
US6961608B2 (en) | 2000-06-05 | 2005-11-01 | Kabushiki Kaisha Toshiba | Interventional MR imaging with detection and display of device position |
US6991652B2 (en) | 2000-06-13 | 2006-01-31 | Burg Karen J L | Tissue engineering composite |
US20020077693A1 (en) | 2000-12-19 | 2002-06-20 | Barclay Bruce J. | Covered, coiled drug delivery stent and method |
US6394965B1 (en) | 2000-08-15 | 2002-05-28 | Carbon Medical Technologies, Inc. | Tissue marking using biocompatible microparticles |
JP2004508884A (en) | 2000-09-25 | 2004-03-25 | コヒージョン テクノロジーズ, インコーポレイテッド | Resorbable anastomotic stent and plug |
US6716444B1 (en) | 2000-09-28 | 2004-04-06 | Advanced Cardiovascular Systems, Inc. | Barriers for polymer-coated implantable medical devices and methods for making the same |
US7261735B2 (en) | 2001-05-07 | 2007-08-28 | Cordis Corporation | Local drug delivery devices and methods for maintaining the drug coatings thereon |
US6746773B2 (en) | 2000-09-29 | 2004-06-08 | Ethicon, Inc. | Coatings for medical devices |
US6863685B2 (en) | 2001-03-29 | 2005-03-08 | Cordis Corporation | Radiopacity intraluminal medical device |
US6730044B2 (en) | 2000-10-13 | 2004-05-04 | Ethicon Endo-Surgery, Inc. | Firing mechanism for use in a surgical biopsy device |
US6712774B2 (en) | 2000-10-13 | 2004-03-30 | James W. Voegele | Lockout for a surgical biopsy device |
US6540694B1 (en) | 2000-10-16 | 2003-04-01 | Sanarus Medical, Inc. | Device for biopsy tumors |
US6544185B2 (en) | 2000-10-23 | 2003-04-08 | Valentino Montegrande | Ultrasound imaging marker and method of use |
US6554760B2 (en) | 2000-10-25 | 2003-04-29 | Gary A. Lamoureux | Pre-loaded needle assembly |
JP4583756B2 (en) | 2000-10-31 | 2010-11-17 | クック インコーポレイテッド | Medical instruments |
US6758824B1 (en) | 2000-11-06 | 2004-07-06 | Suros Surgical Systems, Inc. | Biopsy apparatus |
US6514193B2 (en) | 2000-11-16 | 2003-02-04 | Microspherix Llc | Method of administering a therapeutically active substance |
US20020077687A1 (en) | 2000-12-14 | 2002-06-20 | Ahn Samuel S. | Catheter assembly for treating ischemic tissue |
US6478790B2 (en) | 2000-12-22 | 2002-11-12 | Frank M. Bardani | Implant device and dosage form employable therein |
US6622731B2 (en) | 2001-01-11 | 2003-09-23 | Rita Medical Systems, Inc. | Bone-treatment instrument and method |
US20020095205A1 (en) | 2001-01-12 | 2002-07-18 | Edwin Tarun J. | Encapsulated radiopaque markers |
US6749627B2 (en) | 2001-01-18 | 2004-06-15 | Ev3 Peripheral, Inc. | Grip for stent delivery system |
US7014610B2 (en) | 2001-02-09 | 2006-03-21 | Medtronic, Inc. | Echogenic devices and methods of making and using such devices |
US6636758B2 (en) | 2001-05-01 | 2003-10-21 | Concentric Medical, Inc. | Marker wire and process for using it |
US6824527B2 (en) | 2001-06-07 | 2004-11-30 | Peter Gollobin | Protective sheath for winged needles and sheath and needle assembly |
US8197535B2 (en) | 2001-06-19 | 2012-06-12 | Cordis Corporation | Low profile improved radiopacity intraluminal medical device |
US6702744B2 (en) | 2001-06-20 | 2004-03-09 | Advanced Cardiovascular Systems, Inc. | Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery |
US7160258B2 (en) | 2001-06-26 | 2007-01-09 | Entrack, Inc. | Capsule and method for treating or diagnosing the intestinal tract |
US6648849B2 (en) | 2001-06-27 | 2003-11-18 | Ethicon, Inc. | Medicinal implant and device and method for loading and delivering implants containing drugs and cells |
ATE294535T1 (en) | 2001-07-26 | 2005-05-15 | Univ Oregon Health Sciences | CLOSURE DEVICE FOR A VESSEL AND ATTACHMENT DEVICE |
US7497862B2 (en) | 2001-08-03 | 2009-03-03 | Tyco Healthcare Group Lp | Tissue marking apparatus and method |
US6913626B2 (en) | 2001-08-14 | 2005-07-05 | Mcghan Jim J. | Medical implant having bioabsorbable textured surface |
US6605047B2 (en) | 2001-09-10 | 2003-08-12 | Vivant Medical, Inc. | Biopsy marker delivery system |
US7135978B2 (en) | 2001-09-14 | 2006-11-14 | Calypso Medical Technologies, Inc. | Miniature resonating marker assembly |
US7294118B2 (en) | 2001-10-24 | 2007-11-13 | Becton, Dickinson And Company | Retractable needle assembly |
US6939318B2 (en) | 2002-05-03 | 2005-09-06 | Boston Scientific Scimed, Inc. | Method, tool, and system for deploying an implant into the body |
US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
US20030225420A1 (en) * | 2002-03-11 | 2003-12-04 | Wardle John L. | Surgical coils and methods of deploying |
US7527610B2 (en) | 2002-03-29 | 2009-05-05 | Bioform Medical, Inc. | Connection indicator for a medical delivery/extraction system |
EP1495130A4 (en) | 2002-04-03 | 2006-07-05 | Agy Therapeutics Inc | Use of biomolecular targets in the treatment and visualization of brain tumors |
US20030191355A1 (en) | 2002-04-04 | 2003-10-09 | Ferguson Patrick J. | Hollow bioabsorbable elements for positioning material in living tissue |
US6818668B2 (en) | 2002-04-12 | 2004-11-16 | Biotest Laboratories, Llc | 5-alkyl-7-alkylcarbonate-isoflavone ester and related method |
US20030199887A1 (en) | 2002-04-23 | 2003-10-23 | David Ferrera | Filamentous embolization device and method of use |
US6652442B2 (en) | 2002-04-23 | 2003-11-25 | Acueity, Inc. | Micro-endoscope assembly for intraductal brachytherapy of a mammary duct and method of using same |
US6780179B2 (en) | 2002-05-22 | 2004-08-24 | Rubicor Medical, Inc. | Methods and systems for in situ tissue marking and orientation stabilization |
US6992233B2 (en) | 2002-05-31 | 2006-01-31 | Medafor, Inc. | Material delivery system |
US7166133B2 (en) | 2002-06-13 | 2007-01-23 | Kensey Nash Corporation | Devices and methods for treating defects in the tissue of a living being |
US20040101548A1 (en) | 2002-11-26 | 2004-05-27 | Pendharkar Sanyog Manohar | Hemostatic wound dressing containing aldehyde-modified polysaccharide |
EP2851097A3 (en) | 2002-07-12 | 2015-06-10 | Cook Medical Technologies LLC | Drug-coated angioplasty balloons |
US20040016195A1 (en) | 2002-07-24 | 2004-01-29 | Archuleta John Paul | Foamed glass article for use as thermal energy control media |
DE60318595T2 (en) | 2002-08-01 | 2009-01-08 | James E. Birmingham Selis | biopsy devices |
US20040106891A1 (en) | 2002-08-30 | 2004-06-03 | Inrad, Inc. | Localizing needle with fluid delivery |
US20040116802A1 (en) | 2002-10-05 | 2004-06-17 | Jessop Precision Products, Inc. | Medical imaging marker |
US8027712B2 (en) | 2002-10-11 | 2011-09-27 | Ion Beam Applications S.A. | Elongated markers for soft tissue volume identification |
US6994712B1 (en) | 2002-11-12 | 2006-02-07 | Biopsy Sciences, Llc | Bioabsorbable marker having external anchoring means |
CA2506285C (en) | 2002-11-18 | 2010-05-11 | Richard M. Chesbrough | Tissue localizing and marking device and method of using same |
US20060036158A1 (en) | 2003-11-17 | 2006-02-16 | Inrad, Inc. | Self-contained, self-piercing, side-expelling marking apparatus |
US8137288B2 (en) | 2002-11-20 | 2012-03-20 | Boston Scientific Scimed, Inc. | Medical instrument |
US7008382B2 (en) | 2002-11-20 | 2006-03-07 | Scimed Life Systems, Inc. | Medical instrument |
US7247160B2 (en) | 2002-12-30 | 2007-07-24 | Calypso Medical Technologies, Inc. | Apparatuses and methods for percutaneously implanting objects in patients |
US6889833B2 (en) | 2002-12-30 | 2005-05-10 | Calypso Medical Technologies, Inc. | Packaged systems for implanting markers in a patient and methods for manufacturing and using such systems |
US20040133124A1 (en) | 2003-01-06 | 2004-07-08 | Cook Incorporated. | Flexible biopsy needle |
WO2004075789A2 (en) | 2003-02-26 | 2004-09-10 | Cook Incorporated | PROTHESIS ADAPTED FOR PLACEDd UNDER EXTERNAL IMAGING |
US8372112B2 (en) | 2003-04-11 | 2013-02-12 | St. Jude Medical, Cardiology Division, Inc. | Closure devices, related delivery methods, and related methods of use |
US8383158B2 (en) | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
US7306580B2 (en) | 2003-04-16 | 2007-12-11 | Cook Incorporated | Medical device with therapeutic agents |
US6945973B2 (en) | 2003-05-01 | 2005-09-20 | Nuvasive, Inc. | Slidable bone plate system |
US7877133B2 (en) | 2003-05-23 | 2011-01-25 | Senorx, Inc. | Marker or filler forming fluid |
US20050119562A1 (en) | 2003-05-23 | 2005-06-02 | Senorx, Inc. | Fibrous marker formed of synthetic polymer strands |
US7783336B2 (en) | 2003-06-06 | 2010-08-24 | Ethicon Endo-Surgery, Inc. | Subcutaneous biopsy cavity marker device |
US20040265371A1 (en) | 2003-06-25 | 2004-12-30 | Looney Dwayne Lee | Hemostatic devices and methods of making same |
US7537788B2 (en) * | 2003-07-25 | 2009-05-26 | Rubicor Medical, Inc. | Post-biopsy cavity treatment implants and methods |
US20050033157A1 (en) | 2003-07-25 | 2005-02-10 | Klein Dean A. | Multi-modality marking material and method |
US7744852B2 (en) | 2003-07-25 | 2010-06-29 | Rubicor Medical, Llc | Methods and systems for marking post biopsy cavity sites |
US20050049634A1 (en) | 2003-08-07 | 2005-03-03 | Scimed Life Systems, Inc. | Medical closure device |
US7790141B2 (en) | 2003-08-11 | 2010-09-07 | Pathak Holdings, Llc | Radio-opaque compounds, compositions containing same and methods of their synthesis and use |
US7001341B2 (en) | 2003-08-13 | 2006-02-21 | Scimed Life Systems, Inc. | Marking biopsy sites |
US20050059887A1 (en) | 2003-09-16 | 2005-03-17 | Hassan Mostafavi | Localization of a target using in vivo markers |
WO2005037338A1 (en) | 2003-10-14 | 2005-04-28 | Cook Incorporated | Hydrophilic coated medical device |
US20050148512A1 (en) | 2003-11-10 | 2005-07-07 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
US20050273002A1 (en) | 2004-06-04 | 2005-12-08 | Goosen Ryan L | Multi-mode imaging marker |
AU2004293075A1 (en) | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Soft tissue implants and anti-scarring agents |
EP1689308A1 (en) | 2003-11-26 | 2006-08-16 | Invivo Germany GmbH | Tissue marker and method and apparatus for deploying the marker |
US20050113659A1 (en) | 2003-11-26 | 2005-05-26 | Albert Pothier | Device for data input for surgical navigation system |
US7761138B2 (en) | 2004-03-12 | 2010-07-20 | Boston Scientific Scimed, Inc. | MRI and X-ray visualization |
WO2005087221A1 (en) | 2004-03-15 | 2005-09-22 | Christine Allen | Biodegradable biocompatible implant and method of manufacturing same |
US20050234336A1 (en) | 2004-03-26 | 2005-10-20 | Beckman Andrew T | Apparatus and method for marking tissue |
US9638770B2 (en) | 2004-05-21 | 2017-05-02 | Devicor Medical Products, Inc. | MRI biopsy apparatus incorporating an imageable penetrating portion |
US8075568B2 (en) | 2004-06-11 | 2011-12-13 | Selis James E | Biopsy devices and methods |
DE102004030391A1 (en) | 2004-06-23 | 2006-01-26 | Somatex Medical Technologies Gmbh | marker |
EP1771223A4 (en) | 2004-07-23 | 2009-04-22 | Calypso Med Technologies Inc | Apparatuses and methods for percutaneously implanting objects in patients |
US20080097199A1 (en) | 2004-08-20 | 2008-04-24 | David Mullen | Tissue Marking Devices and Systems |
US8280486B2 (en) | 2004-10-13 | 2012-10-02 | Suros Surgical Systems, Inc. | Site marker visable under multiple modalities |
US20060079805A1 (en) | 2004-10-13 | 2006-04-13 | Miller Michael E | Site marker visable under multiple modalities |
JP5040310B2 (en) | 2004-10-22 | 2012-10-03 | 株式会社カネカ | Treatment catheter |
US8419656B2 (en) | 2004-11-22 | 2013-04-16 | Bard Peripheral Vascular, Inc. | Post decompression marker introducer system |
WO2006056739A2 (en) | 2004-11-23 | 2006-06-01 | Quantum Medical Technology Limited | Surgical tag, magnetometer, and associated system |
KR20070104574A (en) | 2004-12-30 | 2007-10-26 | 신벤션 아게 | Combination comprising an agent providing a signal, an implant material and a drug |
US7577473B2 (en) | 2005-02-03 | 2009-08-18 | Bard Peripheral Vascular, Inc. | Apparatus for subcutaneous placement of an imaging marker |
DE102005012574A1 (en) | 2005-03-18 | 2006-09-21 | Bkh - Technotransfer Gmbh | Markers for animal and human tissue, in particular soft tissue |
US20060217635A1 (en) | 2005-03-24 | 2006-09-28 | Mccombs Elizabeth S | Biopsy device marker deployment |
EP1874215A2 (en) | 2005-03-31 | 2008-01-09 | Cytyc Corporation | Internal biopsy marking |
US20060241385A1 (en) | 2005-04-12 | 2006-10-26 | Ethicon Endo-Surgery, Inc. | Guided disposable fiducial for breast biopsy localization fixture |
US10357328B2 (en) | 2005-04-20 | 2019-07-23 | Bard Peripheral Vascular, Inc. and Bard Shannon Limited | Marking device with retractable cannula |
WO2007002060A1 (en) | 2005-06-21 | 2007-01-04 | Naviscan Pet Systems, Inc. | Tissue interventions using nuclear-emission image guidance |
US20060292690A1 (en) | 2005-06-22 | 2006-12-28 | Cesco Bioengineering Co., Ltd. | Method of making cell growth surface |
US7736293B2 (en) | 2005-07-22 | 2010-06-15 | Biocompatibles Uk Limited | Implants for use in brachytherapy and other radiation therapy that resist migration and rotation |
US9498647B2 (en) | 2005-09-23 | 2016-11-22 | Allen B. Kantrowitz | Fiducial marker system for subject movement compensation during medical treatment |
ES2366102T3 (en) | 2005-09-26 | 2011-10-17 | Bard Peripheral Vascular, Inc. | INTRODUCTION SYSTEM OF A MARKER AFTER DECOMPRESSION. |
US8052658B2 (en) * | 2005-10-07 | 2011-11-08 | Bard Peripheral Vascular, Inc. | Drug-eluting tissue marker |
US20070083132A1 (en) | 2005-10-11 | 2007-04-12 | Sharrow James S | Medical device coil |
US7761137B2 (en) | 2005-12-16 | 2010-07-20 | Suros Surgical Systems, Inc. | Biopsy site marker deployment device |
US8118786B2 (en) | 2006-03-29 | 2012-02-21 | Kawasumi Laboratories, Inc. | Guarded medical winged needle assembly |
US20070287933A1 (en) | 2006-06-08 | 2007-12-13 | Chris Phan | Tissue debulking device and method of using the same |
US20080294039A1 (en) | 2006-08-04 | 2008-11-27 | Senorx, Inc. | Assembly with hemostatic and radiographically detectable pellets |
US20090171198A1 (en) | 2006-08-04 | 2009-07-02 | Jones Michael L | Powdered marker |
ES2443526T3 (en) | 2006-10-23 | 2014-02-19 | C.R. Bard, Inc. | Breast marker |
EP2109409B1 (en) | 2006-12-12 | 2018-09-05 | C.R.Bard, Inc. | Multiple imaging mode tissue marker |
US8401622B2 (en) | 2006-12-18 | 2013-03-19 | C. R. Bard, Inc. | Biopsy marker with in situ-generated imaging properties |
US20080177179A1 (en) | 2006-12-19 | 2008-07-24 | Cytyc Corporation | Target Tissue Locator for Image Guided Radiotherapy |
US20090024225A1 (en) | 2007-07-16 | 2009-01-22 | Stubbs James B | Implant for Targeting Therapeutic Procedure |
-
2006
- 2006-10-05 US US11/538,918 patent/US8052658B2/en active Active
- 2006-10-05 CA CA2562580A patent/CA2562580C/en active Active
- 2006-10-06 EP EP06121906.9A patent/EP1772111B1/en active Active
- 2006-10-06 ES ES06121906.9T patent/ES2558979T3/en active Active
-
2011
- 2011-09-30 US US13/250,121 patent/US8486028B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2558979T3 (en) | 2016-02-09 |
CA2562580A1 (en) | 2007-04-07 |
US20070087026A1 (en) | 2007-04-19 |
EP1772111A2 (en) | 2007-04-11 |
US8486028B2 (en) | 2013-07-16 |
EP1772111A3 (en) | 2008-06-18 |
US20120022370A1 (en) | 2012-01-26 |
EP1772111B1 (en) | 2015-11-18 |
US8052658B2 (en) | 2011-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2562580C (en) | Drug-eluting tissue marker | |
US11357960B2 (en) | Devices for delivering substances through an extra-anatomic opening created in an airway | |
CA2373034C (en) | Injection array apparatus and method | |
DE69824175T2 (en) | REFILLABLE STENT AND ADMINISTRATION SYSTEM | |
US6625486B2 (en) | Method and apparatus for intracellular delivery of an agent | |
US8109904B1 (en) | Drug delivery medical devices | |
US20050273049A1 (en) | Drug delivery device using microprojections | |
US20050273075A1 (en) | Method for delivering drugs to the adventitia using device having microprojections | |
US20190183601A1 (en) | Target identification tool for intra-body localization | |
US20150005595A1 (en) | Implantable devices and methods for evaluation of active agents | |
US8292942B2 (en) | Double-balloon delivery system for an implantable eccentric stent | |
US20090087380A1 (en) | Polymer devices for therapeutic applications | |
CN108472064A (en) | Holder | |
US20120041462A1 (en) | Apparatus for forming hole in spongelike bone | |
JP2020512883A (en) | Delivery system for stents with protruding features | |
KR102453419B1 (en) | Biopsy marker | |
WO2015187442A1 (en) | Implantable devices for evaluation of active agents | |
WO2009038792A2 (en) | Polymer devices for therapeutic applications | |
DE202007016424U1 (en) | Minimally invasive medical implants for controlled drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |